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ABSTRACT 
           ABCB10, or ATP binding cassette sub-family B member 10, is a protein localized 
in the mitochondrial inner membrane. It belongs to the ABC transporter family whose 
members are proteins that facilitate substrate transport across various biological 
membranes. It has been found that ABCB10 is required for normal heme biosynthesis 
during erythroid differentiation and also plays a role in protection against the damage 
caused by reactive oxygen species (ROS) production. This protective effect exists both in 
the erythrocyte development and in the heart recovery after the ischemia-reperfusion 
injury. However, as an ABC transporter, its transported substrates are not known, neither 
is the mechanism by which ABCB10 plays a role in protection against ROS damage. In 
this dissertation an 8-azido-ATP photolabeling system is established to study the ATP 
binding and hydrolysis properties of ABCB10. Using this approach, it is found that the 
conserved amino acid residues Gly497 and Lys498 in the Walker A motif of the 
nucleotide binding domain of ABCB10 are required for ATP binding. On the other hand, 
Gly602 in the C-loop motif and Glu624 in the end of the Walker B motif are necessary 
for ATP hydrolysis. In addition, most ABC transporters increase ATP hydrolysis in the 
  vii 
presence of their substrates. Therefore, the 8-azido-ATP photolabeling system can be 
utilized to test potential substrates of ABCB10. Substances related to the heme 
biosynthesis such as δ-aminolevulinic acid (dALA) and the mitochondrial redox state 
such as oxidized glutathione (GSSG) and reduced glutathione (GSH) are tested for this 
purpose. The 8-azido-ATP photolabeling system shows that GSSG stimulates ATP 
hydrolysis without affecting ATP binding, whereas GSH decreases ATP binding. Further 
study shows that the nucleotide binding domain of ABCB10 is glutathionylated at the 
cysteine residue on the position 547 (Cys547), suggesting that GSH may modulate 
ABCB10 activity via the glutathionylation-regulated ATP binding. This is a first insight 
into the molecular mechanism by which the mitochondrial redox state, through the 
regulation by GSH and GSSG, can modulate ABCB10 activity. 
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1 
CHAPTER ONE 
INTRODUCTION 
 
1.1. Discovery of ABCB10 
1.1.1. The heme biosynthesis pathway 
Red blood cells, or erythrocytes, are the most abundant type of blood cells in vertebrates. 
The amount of red blood cells in the human body is around 5 million per ml of the whole 
blood and they possess a flexible oval bi-concave shape. Abnormal to other cell types, 
mature red blood cells do not have nuclei. A unique component that identifies red blood 
cells is called hemoglobin, which is a complex of a globin and an iron-containing 
prosthetic group, heme. Physiologically, heme carries oxygen molecules that diffuse into 
red blood cells passing through lungs and releases oxygen molecules to tissues and 
organs throughout the body. In tissues and organs, red blood cells also collect the 
metabolic product carbon dioxide. Heme then carries its derivative bicarbonate and 
discards them in the form of carbon dioxide in lungs.   
Heme biosynthesis (Figure 1.1.1.) starts inside the mitochondrial matrix with the 
interaction of glycine with succinyl-CoA to form δ-amino-levulinic acid (dALA). This 
interaction is catalyzed by the erythroid-specific enzyme ALAS2 (δ-amino-levulinic acid 
synthase 2) [1, 2]. Defects in the gene encoding ALAS2 causes sideroblastic anemia 
which can be treated with pyridoxine. dALA is then  exported  to  the  cytosol  through  
an  unknown  mechanism. In the cytosol, two dALA molecules form a porphobilinogen 
molecule  catalyzed  by  δ-aminolevulinic  acid  dehydratase,  followed  by  formations of 
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Figure 1.1.1. The pathway of heme biosynthesis [2]. 
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hydroxymethylbilane catalyzed by porphobilinogen deaminase, uroporphyrinogen III 
catalyzed by uroporphyrinogen III synthase, and coproporphyrinogen III (CPIII) 
catalyzed by uroporphyrinogen decarboxylase. Diseases such as lead poisoning anemia, 
acute intermittent porphyria, congenital erythropoietic porphyria and porphyria cutanea 
tarda are caused by defects in the above four enzymes, respectively. After the production 
of CPIII, the heme biosynthesis pathway goes back into the mitochondrial matrix, during 
which step CPIII is believed to be transported into the mitochondrial inter-membrane 
space by ABCB6, an ABC transporter in the mitochondrial outer membrane [3]. When 
CPIII is passing through the space, it is converted into protoporphyrinogen IX, catalyzed 
by CPIII oxidase, which is loosely bound to the mitochondrial inner membrane [4]. Then 
inside the mitochondrial matrix, protoporphyrinogen IX oxidase catalyzed 
protoporphyrinogen IX into the heme precursor, protoporphyrin IX (PPIX), which is a 
heterocyclic ring composed of four pyrrolic groups. When the ferrous iron (Fe
2+
) is 
chelated in the center of PPIX, the final product heme is formed. Defects in the last three 
steps occurring inside mitochondria result in diseases of hereditary coproporphyria, 
variegate porphyria and erythropoietic protoporphyria, respectively.  
1.1.2. GATA-1 regulated expression of genes during erythropoiesis 
As mentioned above, the initial step in the heme biosynthesis pathway is mediated by 
ALAS2.  The expression of this enzyme is regulated by GATA-1 [5], a transcription 
factor that is essential for erythrocyte, megakyrocyte, mast cell, and eosinophil 
differentiation. It contains a zinc finger DNA binding domain that recognizes a consensus 
sequence existing in regulatory elements of the erythroid cell-specific genes, 
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(A/T)GATA(A/G) [6].  The GATA consensus sequence is abundant in the genome and 
can be found in the promoters of a wide variety of genes, most of which are related to 
erythroid differentiation. In addition to the heme biosynthesis enzyme ALAS2, the 
GATA-1 downstream target genes also include α- and β-globins [7, 8], essential 
components of hemoglobins; bcl-XL [9], an anti-apoptotic protein that promotes erythroid 
cell survival; erythropoietin (Epo), a major growth factor for erythroid cells [10], and its 
receptor (EpoR) [11]; GATA-2 [12], another transcription factor of the GATA family 
that regulates hematopoietic differentiation, etc.  
To search the downstream target genes that are regulated by GATA-1, G1E cells, which 
are a murine GATA-1
-
 erythroid cell line, were used [13, 14]. G1E cells proliferate in 
culture as proerythroblasts and can complete the terminal stage of erythropoiesis if the 
GATA-1 function is restored. More specifically, a conditional GATA-1 cell line (G1E-
ER2) was established by fusing the GATA-1 coding region with the ligand binding 
domain of the estrogen receptor (ER). In a regular cell culture, G1E-ER2 cells 
proliferated as proerythroblasts, the same as G1E cells. However when G1E-ER2 cells 
were treated with β-estradiol, they started to express the GATA-1/ER fusion protein, 
arrest proliferation and initiate terminal erythroid differentiation [9]. The PCR-based 
subtraction screen was performed to identify the transcripts that were induced by GATA-
1 in the β-estradiol-treated G1E-ER2 cells. Among those induced transcripts, most of 
them were well-characterized as erythroid maturation-associated genes. However this 
approach also identified a transcript encoding a protein that is transcriptionally induced 
during the late stage of erythroid differentiation. It was initially named as ABC-me (ATP 
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binding cassette-mitochondrial erythroid) and now is renamed, according to the 
nomenclature established for ABC transporter proteins, as ABCB10 (ATP binding 
cassette, sub-family B, member 10) [15]. 
1.1.3. Expression pattern, sequence and localization of ABCB10 
Northern blot and in situ analysis of mRNA shows that ABCB10 is most abundantly 
expressed in tissues involved in hematopoiesis, such as bone marrow and fetal liver. 
Some other adult tissues like liver, heart and kidneys also express ABCB10. Among 
various in vitro hematopoietic colonies that are differentiated from murine embryonic 
stem (ES) cells, ABCB10 is most abundantly expressed in the erythroid colonies, which 
indicates that ABCB10 is relevant in cell types with high levels of heme production. In 
addition, ABCB10 is not expressed in erythroid colonies derived from GATA-1 knockout 
ES cells, a proof further showing that ABCB10 expression is regulated by GATA-1 [15].  
ABCB10 contains 715 amino acids. The first 105 amino acids encode a mitochondrial 
targeting sequence [16]. Between amino acids 150 and 400, there are three groups 
affluent with hydrophobic residues. Each group is a membrane-spanning loop that 
possesses two transmembrane domains. The amino acids following these groups consist 
of a conserved ATP-binding sequence that can be found in other proteins belonging to the 
ATP binding cassette transporter family. The most three conserved motifs in this 
sequence are GPSGSGKST (the Walker A motif), LSGGQ (the C-loop), and ILLLDE 
(the Walker B motif) [15].  
Both confocal fluorescence microscopy using the mitochondria-specific dye MitoTracker 
or tetramethyl rhodamine ethyl ester (TMRE) and Western blot analysis of the 
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mitochondrial fraction have shown that ABCB10 is localized in the mitochondrial inner 
membrane, with the conserved ATP-binding sequence facing the mitochondrial matrix 
[15].  
In summary, ABCB10 is a protein inserted within the mitochondrial inner membrane 
through the hydrophobic loops and contains a conserved ATP-binding domain inside the 
mitochondrial matrix. 
 
1.2. Overview of ABC transporter proteins 
1.2.1. Structures and working mechanism of ABC transporters 
The ATP binding cassette (ABC) transporters are trans-membrane proteins that work as 
pumps to actively transport substrates across biological membranes. They exist in the 
plasma membrane of both prokaryotes and eukaryotes [17] as well as in the membranes 
of various intracellular organelles, including endoplasmic reticulum, Golgi apparatus, 
peroxisomes, mitochondria [18, 19, 20, 21], and others. By importing or exporting ions, 
sugars, amino acids, peptides, metabolites and drugs, ABC transporters maintain the 
cellular physiological functions in a wide variety of aspects, such as secretion of 
metabolites, signal transduction, antigen presentation, drug resistance, and secretion of 
cytotoxic compounds [22, 23, 24, 25, 26]. Due to their performance of multiple functions 
and presence in all extant phyla, ABC transporter members consist of one of the largest 
and most ancient protein superfamilies in nature.  
Although different ABC transporters possess different functions in various cells and 
tissues, they share similar conserved structures and work in a very similar way. 
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Generally, ABC transporters have two half transporters, each of which contains one 
hydrophobic transmembrane domain (TMD) spanning the membrane 6 times via α 
helices and one hydrophilic nucleotide binding domain (NBD) that binds to and 
hydrolyzes ATP to provide energy for substrate transport [27]. TMD is usually in the 
amino-terminal of the whole molecule and is highly variable in different ABC 
transporters. It works like a vehicle in the ABC transporter through which substrate 
crosses the membrane. NBD is usually in the carboxyl-terminal of the protein and is 
responsible for ATP binding and hydrolysis, which are required for transport. It contains 
highly conserved structures, the most important of which are the Walker A motif 
(GXXGXGKST, X is any amino acid), the Walker B motif (HHHHDE, H is a 
hydrophobic amino acid) and the C-Loop motif (LSGGQ). During a typical transport 
process, two ATP molecules are sandwiched between the Walker A and Walker B of one 
NBD monomer and the C-Loop of the other. In this way, the two NBDs form a sandwich 
dimer with a head to tail orientation [28] and conduct the ATP hydrolysis cycle. The 
hydrolysis step is as follows: 1) ATP binding, 2) ATP hydrolysis and formation of a 
transition state complex in which both ADP and Pi remain bound, 3) release of Pi, and 4) 
release of ADP [29, 30]. After a complete ATP hydrolysis cycle, NBDs bind to new ATP 
to allow the ATP hydrolysis cycles to proceed. 
In detail, specific amino acid residues in the conserved sequences of the Walker A, 
Walker B and C-loop motifs are of significance for the effective ATP binding and 
hydrolysis by NBD of ABC transporters. Binding of ATP by NBD is facilitated by 
several factors. First, the Walker A motif forms a loop that binds to the α- and β-
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phosphates of ATP via several hydrogen bond interactions between the lysine and glycine 
residues and two oxygen atoms from the α- and β-phosphates. Two of the oxygen atoms 
in the γ-phosphate interact with the serine and lysine residues in the Walker A motif via 
hydrogen bonds and the ion Mg
2+ 
coordinates the third oxygen atom [31, 32]. Mg
2+
 
coordination also involves the aspartic acid residue in the Walker B motif, which leads to 
its interaction with the γ-phosphate [33]. The γ-phosphate also interacts with the C-loop 
motif of the opposite monomer [34]. Secondly a highly conserved aromatic residue 
approximately 25 amino acids upstream of the Walker A motif interacts with the adenine 
ring of ATP [35, 36]. Stabilized binding of the α- and β-phosphates of ATP by the 
Walker A motif and the proper positioning of the γ-phosphate are essential for the 
subsequent ATP hydrolysis. During ATP hydrolysis, the γ-phosphate is attacked by the 
water molecule, which is catalyzed by the glutamate residue in the Walker B motif [37].  
Mutations in those conserved amino acids in NBD could lead to defective ATP binding 
and hydrolysis. For example, the study of the prokaryotic ABC transporter histidine 
permease (HisP) of Salmonella typhimurium shows that the mutation of glycine, a 
nonpolar amino acid, to either aspartic acid, a negatively charged amino acid (G39D, 
GSSGSGKST to DSSGSGKST), or serine, a polar uncharged amino acid (G44S, 
GSSGSGKST to GSSGSSKST), reduced ATP binding capacity to below 5% or 5-20% of 
that of the wild type transporter, respectively [38]. In both NBDs of a human ABC 
transporter MDR1 (multidrug resistance 1), mutations of lysine, a hydrophilic amino acid 
in the Walker A motif, to methionine, a hydrophobic amino acid (K433M and K1076M, 
GSSGCGKST to GSSGCGMST), resulted in decreased ATP binding affinity [39]. In the 
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Walker A motif of mouse MDR1, the mutation of glycine to alanine (G431A and/or 
G1073A, GSSGCGKST to GSSGCAKST), both of which are non-polar hydrophobic 
amino acids, or the mutation of lysine to arginine (K432R and/or K1074R, GSSGCGKST 
to GSSGCGRST), both of which are positively charged hydrophilic amino acids, resulted 
in almost complete loss of the ATP hydrolysis activity and abolishment of the ability to 
confer drug resistance [40]. In the C-loop motif of the ATPase Rad50, the mutation of 
serine to arginine (S793R, LSGGE to LRGGE), both of which are hydrophilic amino 
acids, caused decreased ATP hydrolysis [41]. And this phenomenon also occurs in 
MDR1 that has a mutation of glycine to valine (G534V or G1179V, LSGGQ to LSGVQ), 
both of which are non-polar hydrophobic amino acids [42]. These results suggest that the 
C-loop motif plays a role in the cooperative and allosteric control of ATP hydrolysis. 
And it is further confirmed by the fact that mutation of leucine or glycine in the C-loop of 
TAP1 fully abolished its peptide transport function due to the defect in energy 
transduction by ATP hydrolysis [43]. 
The amino acid residue variability in TMDs determines substrate specificities of ABC 
transporters. For example, in the first transmembrane domain (TM1) of human MDR1, 
the replacement of histidine by arginine (H61R), both of which are positively charged 
amino acids except that the later contains a bulkier side chain, resulted in reduced 
resistance to vinblastine and adriamycin (doxorubicin), but increased resistance to 
colchicine and VP16. Changes in drug resistance profiles were examined by randomly 
replacing one of the amino acid residues between alanine 57 and leucine 65 in TM1, all 
of which are small and neutral amino acids, with arginine, a bulkier and basic amino acid. 
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This approach helped discover that histidine 61, glycine 64 and leucine 65 were essential 
for formation of the recognition site for substrates [44]. Other studies have shown that a 
key substrate handling region is located in the loop between the second and third 
transmembrane α-helices (TM2 and TM3). A mutation of glycine to valine in this region, 
both of which are non-polar hydrophobic amino acids (G185V), caused increased 
stimulation of ATP hydrolysis by colchicine and etoposide, while slightly decreased 
stimulation by vincristine. Also no changes in ATP hydrolysis were observed if this 
mutant was treated by verapamil and vinblastine. These changes in ATP hydrolysis 
activity were consistent with the changes in drug resistance profiles, suggesting that this 
loop region between TM2 and TM3 is essential for substrate recognition and that the 
extent of ATP hydrolysis for energy transduction is dependent upon substrate recognition 
in TMDs [39].  
During the transport process, TMDs undergo four key steps, including: 1) substrate 
recognition, 2) high to low affinity conformational transition in the substrate binding 
sites, 3) energy consumption, and 4) switching back to the basal high affinity 
conformation. As mentioned above, the conformational transition in TMDs are coupled 
with the ATP binding and hydrolysis (Figure 1.2.1.1.) [45]. 
Studies in HisP have shown that TMDs communicate with NBDs through two special 
flexible TMD:NBD interface structures, the α-domain and the Q-loop motif. The α-
domain contains several α-helices (the α3, α4, α4” and α5 regions), while the Q-loop 
motif contains a conserved glutamine residue, which is an ATP hydrolysis catalytic site, 
and  the  subsequent  8-  or  9-residue  segment.  The  ATP  hydrolysis occurring in the γ- 
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Figure 1.2.1.1. Model for TMD-NBD-coupled transport of substrate. The complete 
transport process involves conformational transitions of TMDs and NBDs as well as 
interactions of the substrate and nucleotides with the transporter. The substrate is 
transported from the side proximal to NBDs to the side away from NBDs. A) The facing-
inward and high affinity conformation of TMDs and the separate conformation of NBDs. 
B) Substrate binding by TMDs in the facing-inward and high affinity conformation. C) 
ATP binding by NBDs in the separate conformation. D) Transition from the separate 
conformation to the engaged conformation in NBDs. E) Transition from the facing-
inward and high affinity conformation to the facing-outward and low affinity 
conformation in TMDs. F) Release of the substrate. G) ATP hydrolysis. H) Release of the 
γ-phosphate. I) Transition from the engaged conformation to the separate conformation in 
NBDs. J) Transition from the facing-outward and low affinity conformation to the facing-
inward and high affinity conformation in TMDs. 
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phosphate caused conformational changes in the attached serine and second glycine 
residues in the C-loop motif (LSGGQ). These conformational changes are propagated to 
the α4” domain and are amplified via the fulcrum and lever rotation performed by the α3 
and α5 domains. The carboxyl- terminal of the Q-loop coordinates with the α-domain at 
the α4” region and this coordination forms a hinge-bending movement in NBDs, which 
helps to relay conformational changes to TMDs for substrate transport. On the other 
hand, when the substrate is not available, TMDs block the conformational changes in the 
α-domain via an α-swivel to prevent the C-loop motif from engaging the opposite ATP 
catalytic site in the Q-loop motif (Figure 1.2.1.2.) [46]. 
 
 
 
Figure 1.2.1.2. Ribbon diagram of the HisP ATP-binding domain from S. 
typhimurium [46]. The NBD core domain is in blue. The α-domain is in red. The Q-loop 
motif is in yellow. The α-swivel (α-sw) is in magenta. The catalytic glutamine residue 
(Q100) in the Q-loop motif is shown in ball. Two ATP molecules are shown in stick, with 
oxygen atoms in red, carbon in gray, nitrogen in blue, and phosphorus in yellow. The γ-
phosphate in one ATP molecule interacts with conserved residues in the C-loop motif 
(LSGGQ).  
 
 
 
 
13 
1.2.2. The superfamilies of ABC transporters 
Currently, 49 ABC transporter genes have been identified in the human genome. By 
analyzing phylogenetics and comparing their amino acid sequences, these 49 ABC 
transporters can be classified into 7 superfamilies: ABCA and through ABCG (Table 
1.2.2.).  
 
Table 1.2.2. ABC transporter superfamilies 
Superfamily Number of 
members 
Representative Function 
ABCA 
 
      ABCB 
 
 
 
ABCC 
 
 
ABCD 
ABCE 
 
ABCF 
ABCG 
12 
 
11 
 
 
 
13 
 
 
          4 
1 
 
3 
5 
ABCA1 
ABCA4 
MDR 
TAP 
ABCB10 
 
CFTR 
SUR 
MRP 
ALDP 
ABCE1 
 
ABCF1 
ABCG1 
ABCG2 
Trafficking of lipids 
Retinoids transport 
Drug resistance 
Antigen peptide presentation 
Heme production, protection 
 against ROS damage 
Cl
-
 flow 
KATP channel 
Secretion of toxins 
Transport of CoA esters 
Regulation of viral infection, cell  
proliferation, anti-apoptosis 
mRNA translation 
Macrophage cholesterol efflux 
Drug resistance 
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For the ABCA superfamily, there are a total of 12 full ABC transporters, most of which 
are among the largest ABC transporters with more than 2,100 amino acid residues [47]. 
The largest one of all is ABCA13, spanning over 450 kb in the genome, splitting into 62 
exons and translating into 5,058 amino acids of the full-length protein [48]. Typical ABC 
transporters belonging to this superfamily include ABCA1 which conducts cellular 
trafficking of lipids [49], and ABCA4 which transports retinoids across disc membranes 
in the outer segment of rod photoreceptor cells [50]. 
The ABCB superfamily only exists in mammals and has 11 members. 4 of them are full 
transporters and 7 are half transporters. ABCB1, also called multidrug resistance protein 
(MDR1) or p-glycoprotein, is a representative of this superfamily and its function is to 
confer drug resistance to cancer cells [51]. This mechanism causes ineffectiveness in 
cancer treatment by chemicals. Another well-known one is ABCB3, or the so-called 
transporter antigen processing protein (TAP), which mediates the transport of peptides 
from cytosol into ER to form the MHC complex during the MHC class I antigen 
presentation pathway [52]. ABCB10, together with other mammalian mitochondrial ABC 
transporters ABCB6, 7 and 8, belongs to this superfamily [15, 3, 53, 54,]. 
The ABCC superfamily contains 13 members and the most famous one is ABCC7, or the 
so-called CFTR (cystic fibrosis transmembrane conductance receptor). Instead of 
facilitating transport of substrates across membranes as most of other ABC transporters 
do, ATP-driven conformational changes in CFTR cause opening and closing of a gate so 
that the anions (eg. Cl
-
) flow down their electrochemical gradient and pass through the 
plasma membrane [55]. Another ABC transporter in this group is SUR (sulfonylurea 
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receptor). It is not related to any substrate transport function, but plays a role in 
association with the potassium channel proteins Kir6.1 or Kir6.2 to form the ATP-
sensitive potassium channel (KATP) [56]. Besides facilitating ion flux, other members in 
this superfamily are identified as multidrug-resistance proteins (MRP) and are involved 
in secretion of toxins. An example of this type is cMOAT/ABCC2 (canalicular 
multispecific organic anion transporter) which exports glucuronide, oxidized glutathione 
(GSSG) and glutathione-conjugates (GS-X) [57].  
The ABCD superfamily has 4 genes and they all encode half-transporters. These half-
transporters pair one another to form intact transporters (homodimers or heterodimers). 
The ABCD transporters are only present in peroxisomes. For example, ABCD1, or the 
so-called ALDP (adrenoleukodystrophy protein) transports coenzyme A esters of very-
long-chain fatty acids across the peroxisomal membrane [58]. 
There is only one protein in the ABCE superfamily, which is ABCE1. It only possesses 
the nucleotide binding domains and does not have the transmembrane domains. Therefore 
its function is not related to transport. ABCE1 interacts with RNase L to form a 
heterodimer, and this heterodimer complex inhibits the interferon-dependent 2-5A (5'-
phosphorylated 2',5'-linked oligoadenylates)/RNase L system and regulate viral infection, 
tumor cell proliferation and anti-apoptosis [59].  
Similar to ABCE, ABCF proteins also only have the nucleotide binding domains and lack 
the transmembrane domains. There are 3 members in this superfamily. One example is 
ABCF1. It is not a membrane-associated transporter, but is associated with eukaryotic 
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initiation factor 2 (eIF2) and ribosomal subunits in the presence of ATP to control mRNA 
translation [60]. 
The structure of ABCG transporters is opposite to those in other ABC transporter 
superfamilies. Their nucleotide binding domains are in the amino terminus while the 
transmembrane domains are in the carboxyl terminus. A total of 5 transporters belong to 
this superfamily. For example, ABCG1 helps macrophage cholesterol efflux, and 
ABCG2, similar to MDR1, makes cells resistant to anti-cancer drugs such as 
mitoxantronme, doxorubicin, and daunorubicin [61, 62]. 
 
1.3. ATP binding cassette sub-family B, member 10 (ABCB10) 
1.3.1. The structure of ABCB10 
Unlike the MDR1 gene encoding a complete transporter composed of two monomers, the 
ABCB10 gene only encodes a half transporter containing one TMD that spans the 
mitochondrial inner membrane six times with α-helices and one NBD that binds to and 
hydrolyzes ATP. Two identical half transporters form a homodimer, a complete ABCB10 
transporter [16]. MDL1 (multidrug resistance-like 1) is the yeast ortholog of ABCB10. It 
is also a half transporter localized in the mitochondrial inner membrane [63]. By 
comparing the sequences, ABCB10 and MDL1 have a moderate degree of homology 
(43% identity, covering 78% of the amino acid sequences). Further, each MDL1 
monomer also spans the mitochondrial inner membrane six times and its NBD is at the 
carboxyl-terminal and facing the mitochondrial matrix. The substrates exported by 
MDL1 were shown to be small peptides with molecular masses between 600 and 2100 
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Daltons. They are the proteolysis products of the mitochondrial proteins degraded by the 
m-AAA protease inside the mitochondrial matrix [64]. Similar to other ABC transporters 
mentioned above, the conserved glutamate residue in the end of the Walker B motif of 
MDL1 is essential for ATP hydrolysis but is not related to ATP binding [65]. In addition, 
ABCB10 also has two other orthologs in C. elegans, haf-3 (44% identity, covering 79% 
of the sequence) and haf-1 (40% identity, covering 70% of the sequence) [66].  
The structure of human ABCB10 has been recently resolved. The structure shows that 
TMD, before entering the mitochondrial inner membrane with six α-helices, has another 
short α-helix lying parallel to the plane of the mitochondrial inner membrane at the 
matrix side. The beginning of this α-helix region is exactly the site where the 
mitochondrial targeting sequence is cut off after ABCB10 has been introduced into 
mitochondria [67, 16]. The carboxyl-terminal of TMD projects into the mitochondrial 
matrix for 30 Å in length. TMDs from two half transporters are connected with each 
other via the interaction of TM4 and TM5 from one half transporter with TM1-3 and 
TM6 from the other (Figure 1.3.1.).  
As indicated in the figure 1.2.1.1, for most ABC transporters, in the absence of ATP, 
TMDs maintain an open-inward conformation with the substrate binding site facing the 
separate NBDs, while the binding of ATP causes the packing of NBDs and the 
sandwiching of two ATP, followed by the open-outward conformational change in the 
TMDs. However, for ABCB10, the binding of ATP does not directly lead to the change 
in the TMD conformation from the open-inward to the open-outward [67].  The possible 
reason  is  that  the  binding  of  ATP  in  the  absence of the substrate does not trigger the 
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Figure 1.3.1. Structure of human ABCB10 [67]. Each TMD contains six α-helices and 
each NBD binds to one AMPPCP molecule (in green), an ATP analog. At the N-terminal 
of TMD, there is a small peptide (in red) parallel to the plane of the lipid bilayer.  A) An 
ABCB10 monomer with one TMD and one NBD. B) An ABCB10 homodimer observed 
from two angles. TMDs are in an open-inward conformation and NBDs are separate from 
each other. 
 
packing of two NBDs and therefore one ATP molecule binds to only one NBD via the 
interaction with the Walker A motif and its γ-phosphate is far away from the catalytic 
sites (such as the C-loop motif and the glutamate in the end of the Walker B motif) of the 
other NBD. The ATP switch model suggests that only when two ATP binds to two 
NBDs, TMDs will change from the open-inward conformation to the open-outward 
conformation for substrate transport [68]. Although in the absence of the substrate the γ-
phosphate is far away from the catalytic sites, there is a basal ATP hydrolysis occurring 
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in NBDs. Also common to other ABC transporters, the glutamate in the end of the 
Walker B motif is one of the sites essential for ATP hydrolysis [67].  
1.3.2. The role of ABCB10 in erythropoiesis 
As mentioned above, ABCB10 is most abundantly expressed in erythroid tissues such as 
bone marrow and fetal liver. Besides that, the overexpression of ABCB10 in the murine 
erythroleukemia cells (MEL cells) significantly increases both hemoglobin production 
and synthesis rate after the cells are treated with DMSO for induction of erythroid 
differentiation (Figure 1.3.2.A.) [15]. Silencing of ABCB10 in erythroid leukemia K562 
cells reduces both the heme and globin production [69]. 
In vivo studies in mice have shown that the GATA-1 and GATA-2 double-knockout 
(GATA-1
-/-
 / GATA-2
-/-
) embryos die by day 11.5 pc (post coitus). This embryonic 
lethality is likely caused by defects in primitive erythropoiesis, which results from the 
absence of the GATA-1- and GATA-2-regulated transcription of genes involved in 
erythroid differentiation and function, such as ABCB10 [70]. Another in vivo study 
shows that the ABCB10 knockout (ABCB10
-/-
) mice are also embryonic lethal and die at 
day 12.5 pc, just one day later than the GATA-1
-/- 
/ GATA-2
-/- 
embryos [71]. This one 
day delay in embryonic lethality could be explained by the fact that ABCB10 plays its 
role in a late stage during erythroid differentiation while GATA-1 and GATA-2 regulate 
various erythroid differentiation-associated genes and affect erythroid differentiation in 
all stages. Consistent with the embryonic lethality at day 12.5 pc, the ABCB10
-/-
 embryos 
show severe anemia at day 10.5, demonstrated by the lack of red coloring of the yolk sac 
vasculature (Figure 1.3.2.B.).  
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A 
                                 
 
 
 
B 
 
 
Figure 1.3.2. ABCB10 is essential for hemoglobin production [15, 71]. A) The amount 
of the benzidine-stained hemoglobin is more in the ABCB10-transfected MEL cells (left) 
than in the empty vector-transfected ones (right) during the DMSO-induced 
differentiation. B) An ABCB10
-/-
 embryo at day 10.5 pc does not show hemoglobin 
production in the vasculature (upper right), compared with the wild type one (upper left). 
Reduced erythroid cells were shown in the HE-stained section of yolk sac blood islands 
from ABCB10
-/-
  embryo at day 10.5 pc (lower right), compared with the wild type one 
(lower left). 
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All the above results support that ABCB10 is required for hemoglobin synthesis. 
However, some hemoglobin was still detected in ABCB10
-/-
, demonstrating that 
ABCB10 is not completely essential for heme biosynthesis. This indicates that ABCB10 
defect may reduce heme production via some indirect ways rather than directly blocking 
the heme biosynthesis pathway. Another report suggests that ABCB10 interacts with the 
amino-terminal of the protein mitoferrin-1 (Mfrn1), an iron importer localized in the 
mitochondrial inner membrane. And this interaction leads to the stabilization of Mfrn1 
and therefore enhances the iron import and acquisition in the mitochondria so that heme 
biosynthesis could proceed at high rates. However, this interaction is not essential for 
heme biosynthesis [72]. There is another report showing that inactivation of ABCB10 in 
hematopoietic cells of conditional ABCB10 knockout mice causes accumulation of PPIX 
in reticulocytes and iron deposits in the mitochondria, indicating that in addition to being 
a scaffold for Mfrn1 stabilization, ABCB10 may also coordinate ferrochelatase to 
facilitate chelation of iron to PPIX [73].  
Some other mitochondrial ABC transporters have been shown to participate in heme 
biosynthesis through different mechanisms. For instance, the mitochondrial outer 
membrane protein ABCB6 has been suggested to facilitate the transport of CPIII from the 
cytosol to the mitochondrial inter-membrane space where it is converted into 
protoporphyrinogen IX by coproporphyrinogen oxidase [3, 74]. The mitochondrial inner 
membrane protein ABCB7 promotes cytosolic iron-sulfer cluster (Fe-S cluster) 
biogenesis through the transport of a mitochondrially derived component into the cytosol 
for Fe-S assembly [53]. The ABCB7-mediated Fe-S biogenesis maintains iron 
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homeostasis [75]. And disturbance of iron metabolism due to disruption of ABCB7 can 
inactivate ferrochelatase, one of the eight essential enzymes for heme biosynthesis, and 
then impairing heme production [76]. ABCB8 is involved in mitochondrial iron export 
and is required for maturation of the cytosolic Fe-S proteins [54]. All these are indirect 
proofs that support the hypothesis that ABCB10 is also likely involved in heme 
biosynthesis by transporting certain substrates.  
1.3.3. The role of ABCB10 in protection against ROS damage 
Reactive oxygen species (ROS) are oxygen derivatives including hydroxyl radical (
.
OH), 
hydrogen peroxide (H2O2), superoxide (
.
O2
-
), and peroxide (ROOH). They are normally 
generated during cellular metabolism and cells can protect themselves against ROS 
damage via enzymes like superoxide, dismutases, catalases, glutathione peroxidases and 
peroxiredoxins (Figure 1.3.3.1.). However when cells undergo stress, ROS will be 
overproduced and excessive ROS will damage cells via biological macromolecules. 
Specifically, mitochondria are a major site of cellular ROS production. During oxidative 
phosphorylation process, protons are transported across the mitochondrial inner 
membrane via the electron transport chain. In this way electrons pass through a series of 
proteins until they reduce oxygen molecules to water. If the oxygen molecules are not 
completely reduced after accepting electrons, they will form superoxide (
.
O2
-
), which can 
impair cellular components or generate hydrogen peroxide. Therefore the protection 
against mitochondrial ROS is essential for cell survival and normal functions. 
For ABCB10, in addition to facilitating heme biosynthesis during erythropoiesis, it also 
plays a role in protection against damage caused by ROS. During primitive erythropoesis, 
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ROS production is increased in the ABCB10
-/- 
erythroblasts, which is followed by 
apoptosis. Treatment of the ABCB10
-/- 
erythroid precursor cells with the mitochondrial 
antioxidant MnTBAP could prevent ABCB10
-/- 
embryonic blood precursors from 
apoptosis as well as increase their hemoglobin levels [71]. This report suggests that 
ABCB10 is associated with ROS decrease and it may modulate heme biosynthesis rates 
through regulation of mitochondrial ROS. The heme biosynthesis pathway itself is a pro-
oxidant process and there are three ways by which ROS could be generated: 1) the metal-
catalyzed autoxidation of dALA, 2) the porphyrin-catalyzed photo-oxidation, and 3) the 
heme-catalyzed ROS generation and membrane lipid peroxidation [77].  
As ABCB10 is also expressed in the non-erythroid tissues such as heart, liver and 
kidneys, it may have other functions besides facilitating hemoglobin synthesis. For this 
reason, its role in the ischemia-reperfusion damage of heart has been studied. Research 
shows that inactivation of one allele of ABCB10 (ABCB10 +/-) does not affect basal 
cardiac function, but markedly decreases heart recovery after acute induction of oxidative 
stress by ischemia-reperfusion. This cardiac defect induced by ischemia- reperfusion in 
the ABCB10 +/- hearts could be completely prevented by pre-treatment with antioxidants 
for 20 minutes [78], further confirming that ABCB10 protects against ROS-induced 
damage.  
ROS can be removed through the glutathione oxidation-reduction (GSH-GSSG) cycle 
(Figure 1.3.3.1.), which occurs both in the cytosol and in the mitochondria (Figure 
1.3.3.2.) [79]. Removal of ROS is at the expense of GSH and is coupled with the 
oxidation of GSH to GSSG, catalyzed by glutathione peroxidase. Therefore 
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mitochondrial GSH/GSSG ratio can reflect the local redox state there. In order to 
maintain the high GSH/GSSG ratio so that mitochondria are in healthy reduced state to 
protect themselves from ROS-mediated damage, GSSG should be decreased. One way to 
decrease GSSG is by reducing GSSG back to GSH via GSH reductase using the reducing 
equivalent from NADPH [79, 80]. The other way is by exporting GSSG directly from the 
mitochondria and reducing it in the cytosol. It is known that there are some other ABC 
transporters that can help transport GSSG across plasma membrane and modulate cellular 
oxidative stress [81, 82]. Thus, it is worthy to test whether GSSG can modulate ABCB10 
antioxidant function or whether it can be transported across mitochondrial membrane by 
ABCB10. In addition to the above mechanisms, another enzyme glutathione S-transferase  
(GST)  also  participates  in  the  protection against ROS damage by detoxifying some 
toxic carbonyl-, peroxide- and epoxide-containing metabolites induced during oxidative 
stress [83]. The common function of GST is to catalyze the conjugation of GSH to a wide 
variety of xenobiotic substrates. Further, the conjugate GS-X (X is a substrate) is 
transported out of cells via an ABC transporter. Two typical examples of this kind of 
transport are the export of the glutathione-conjugated endogenous organic anions such as 
GS-LTC4 (conjugation of GSH to leukotriene C4) [84] and the export of some xenobiotic 
metabolites by MRP1 [85]. GSTs also exist in mitochondria, and similar to GSH 
peroxidase, their expressions are increased when there is an overproduction of ROS 
inside mitochondria [86]. In some cases, GSH is not conjugated to the substrates, but they 
are co-transported by ABC transporters. For example, some anti-cancer drugs such as 
vincristine, etoposide and vinblastine are co-transported with GSH out of cells via multi-
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drug resistance proteins [85, 87, 88]. In this regard, GSH itself is also a substrate of 
certain ABC transporters (Figure 1.3.3.3). For these reasons, to find out the molecular 
mechanism of protective effect mediated by ABCB10 on ROS-damaged mitochondria, it 
is necessary to examine the relationship of the ROS-related molecule couple GSH/GSSG 
with ABCB10. Indeed this relationship also has strong connections with the heme 
biosynthesis pathway. Therefore, this dissertation will show a methodology to elucidate 
the relationship of ABCB10’s function with the oxidative stress and redox state inside 
mitochondria. 
 
 
 
Figure 1.3.3.1. The metabolism of reactive oxygen species (ROS). GSH: reduced 
glutathione, GSSG: oxidized glutathione, NADP
+
: nicotinamide adenine dinucleotide 
phosphate, NADPH: reduced nicotinamide adenine dinucleotide phosphate, SOD: 
superoxide dismutase, CAT: catalase, GPx: glutathione peroxidase, GR: glutathione 
reductase. 
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Figure 1.3.3.2. Mitochondrial control of oxidative stress (Mari M, Morales A, Colell 
A, et al.). Gpx: glutathione peroxidase, GR: glutathione reductase, Grx: glutaredoxin, 
MnSOD: Mn-dependent superoxide dismutase, Trx2: thioredoxin-2, TrxR: Trx reductase, 
PrxIII: peroxiredoxin III, GST: glutathione S-transferase. 
 
 
 
Figure 1.3.3.3. GSH-involved substrate transport by ABC transporters (Rothnie A, 
Conseil G, Lau AYT, et al.). A) Transport of a GSH-conjugated substrate, B) Co-
transport of GSH and a substrate, C) GSH-stimulated transport of a substrate, D) 
Modulator-stimulated transport of GSH, E) GSH-independent transport of a substrate. 
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CHAPTER TWO 
MATERIALS 
 
2.1. Chemicals, reagents, enzymes and kits 
Table 2.1. List of chemicals, reagents, enzymes and kits 
Name Source 
ABCB10 real time PCR mixture 
Adenosine 5’-diphosphate sodium salt (ADP) 
Adenosine 5’-monophosphate sodium salt 
(AMP) 
Adenosine 5’-triphosphate sodium salt (ATP) 
Ampicillin 
Anti-V5 agarose affinity gel beads 
Ascorbic acid 
Biotin-labeled glutathione (GSH-biotin) 
β-mercaptoethanol 
Bovine serum albumin (BSA) 
Calcium chloride (CaCl2) 
Collagenase II 
Cytidine 5’-triphosphate sodium 
salt (CTP) 
δ-aminolevulinic acid (dALA) 
Diamide 
DNAseI 
Dulbecco’s modified eagle medium 
(DMEM) with high glucose 
Enhanced chemiluminescence (ECL) kit 
Applied Biosystems 
Sigma Aldrich 
Sigma Aldrich 
 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
A gift from Dr. Markus Bachschmid 
Sigma Aldrich 
Calbiochem 
Sigma Aldrich 
Worthington 
Sigma Aldrich 
 
Sigma Aldrich 
MP Biomedicals 
Sigma Aldrich 
Gibco       
 
Thermo Scientific 
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(Continued) 
Name Source 
EBM-2 endothelial cell growth media 
Endothelial mitogen 
Ethylene diamine tetra acetic acid  
(EDTA) 
Ethylphenyl polyethylene glycerol  
(NP40) 
Ethylene glycol tetra acetic acid (EGTA) 
8-azido-ATP [γ] biotin 
[α-32P] 8-azido-ATP  
ES-Cult FBS for EB differentiation 
ES-Cult FBS for ES cell maintenance 
Ethidium bromide 
Fetal bovine serum (FBS) 
GAPDH real time PCR mixture 
Gelatin, 0.1% 
Glutamine, 100x 
Guanosine 5’-triphosphate sodium 
salt (GTP) 
Hank’s balanced salt solution (HBSS) 
High capacity RNA-to-DNA mini kit 
Horseradish peroxidase-conjugated  
ExtrAvidin (ExtrAvidin-HRP) 
hTransferrin 
Hydrochloric acid (HCl) 1N 
Kanamycin powder 
 
Lonza 
Biomedical Technology 
Boston BioProducts 
 
Mersham Life Science 
 
Fisher Scientific 
Affinity Photoprobes 
Affinity Photoprobes 
Stem Cell Technologies 
Stem Cell Technologies 
Fisher Biotech 
Gibco 
Applied Biosystem 
Millipore 
Gibco 
Sigma Aldrich 
 
HyClone 
Applied Biosystems 
Sigma Aldrich 
 
Sigma Aldrich 
Acros 
Sigma Aldrich 
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(Continued) 
Name Source 
Iscove’s modified Dulbecco’s medium  
(IMDM) 
LB agar 
LB broth 
L.M.P. agarose 
MACS running buffer 
Magnesium chloride (MgCl2) 
MEM non-essential amino acids, 100x 
MethoCult GFM 3434 
Monothioglycerol (MTG) 
MOPS 
MOPS SDS-running buffer, 20x 
Mouse leukemia inhibitory factor (mLIF) 
NE buffer 3, 10x 
N, N-Bis(2-hydroxyethyl)-2-amino- 
Ethanesulfonic acid (BES) 
Nucleosides 
NuPAGE 10% Bis-Tris precast mini gel 
1kb plus DNA ladder 
One Shot Top 10 competent cells 
Opti-MEM media 
Ouabain 
Oxidized glutathione (GSSG) 
Penicillin/streptomycin solution 
Phosphate buffered saline (PBS) 
Phusion high fidelity PCR kit 
Gibco 
 
Invitrogen 
Acros 
Invitrogen Life Technologies 
Miltenyi Biotec 
Fisher chemical 
Gibco 
Stem Cell Technologies 
Sigma Aldrich 
Sigma Aldrich 
Invitrogen 
Gibco 
New England Biolabs 
Sigma Aldrich 
 
Chemicon 
Invitrogen 
Invitrogen 
Invitrogen 
Gibco 
Sigma Aldrich 
Sigma Aldrich 
Mediatech 
Gibco 
Thermo Fisher Scientific 
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(Continued) 
Name Source 
Plasmid mini/maxi-prep kit 
Protease inhibitor 
Protein assay dye reagent concentrate 
Protein free hybridoma medium (PFHM) 
Pyruvate, 100x 
Red blood cell lysis solution 
Reduced glutathione (GSH) 
Restriction enzyme EcoRI 
Restriction enzyme NotI 
RNeasy mini kit 
SDS sample buffer, 6x 
Sodium deoxycholate 
Sodium dodecyl sulfate (SDS), 10% 
Site-directed mutagenesis kit 
Sodium chloride (NaCl) 
Sodium hydroxide (NaOH), 1N 
Sodium phosphate dibasic (Na2HPO4) 
Sodium phosphate monobasic  
(NaH2PO4) 
Sucrose 
T4 DNA ligase kit 
Tert-butyl hydroperoxide 
Thymidine 5’-triphosphate sodium 
salt (TTP) 
Transfer buffer 
Tris-base 
Qiagen 
Calbiochem 
Bio-Rad 
Gibco 
Gibco 
Miltenyi Biotec 
Sigma Aldrich 
New England Biolabs 
New England Biolabs 
Qiagen 
Boston BioProducts 
Fisher Chemical 
Research Genetics 
Agilent Technologies 
Sigma Aldrich 
Acros 
Fisher Chemical 
Fisher Chemical          
 
Fisher Chemical                                                                  
Invitrogen 
Sigma Aldrich 
Sigma Aldrich 
 
Invitrogen 
Fisher BioReagents  
 
 
 
 
31 
(Continued) 
Name Source 
Tris-Borate-EDTA (TBE), 10x solution 
Trypsin, 0.25% 
Tween-20 
Wizard DNA purification kit 
Fisher BioReagents 
Gibco 
Anatrace 
Promega 
 
 
2.2. Plasmids and primers 
Table 2.2.1. List of plasmids 
Name Source 
pEF1α-V5-His Type B 
pEGFP-N1 
Invitrogen Life Technologies 
BD Biosciences Clontech 
 
Table 2.2.2. List of primers for DNA sequencing 
Name Sequence 
ABCB10 anti-sense 273-253 
 
ABCB10 anti-sense 963-939 
 
ABCB10 sense 827-858 
 
ABCB10 sense 1193-1225 
 
ABCB10 sense 1801-1827 
 
5’-CAGGGGATGTGCGGCGCGGGG- 
3’ 
5’-CTCCTCGGCTAGCTGTGTGGCT 
TCTGC-3’ 
5’-CACCAAGTCTGGCCACCTTTGTT 
CTGAGTGTG-3’ 
5’-CCTTCCTCATGTACGCTTTCTGG 
GTTGGATTGA-3’ 
5’-GGTGGGCAGAAGCAGAGGATT 
GCAATA-3’ 
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Table 2.2.3. List of primers for ABCB10 mutagenesis 
Name Sequence 
ABCB10 Walker A mut (G497A) For 
 
ABCB10 Walker A mut (G497A) Rev 
 
ABCB10 Walker A mut (K498R) For 
 
ABCB10 Walker A mut (K498R) Rev 
 
ABCB10 Loop C mut (G602V) For 
 
ABCB10 Loop C mut (G602V) Rev 
 
ABCB10 Loop C mut (G602D) For 
 
ABCB10 Loop C mut (G602D) Rev 
 
ABCB10 Walker B mut (E624Q) For 
 
ABCB10 Walker B mut (E624Q) Rev 
5’-GTTGGCCCAAGTGGTTCTGCGA 
AATCAACAGTGGTTTCG-3’ 
5’-CGAAACCACTGTTGATTTCGCA 
GAACCACTTGGGCCAAC-3’ 
5’-CCAAGTGGTTCTGGGAGATCAA 
CAGTGGTTTCG-3’ 
5’-CGAAACCACTGTTGATCTCCCA 
GAACCACTTGG-3’ 
5’-CATCCTCCTGTCAGGTGTGCAG 
AAGCAGAGGATTG-3’ 
5’-CAATCCTCTGCTTCTGCACACC 
TGACAGGAGGATG-3’ 
5’-CATCCTCCTGTCAGGTGACCAG 
AAGCAGAGGATTGC-3’ 
5’-GCAATCCTCTGCTTCTGGTCAC 
CTGACAGGAGGATG-3’ 
5’-CCCAAAATTCTTCTCCTTGATCA 
AGCAACCAGTGCACTGGATG-3’ 
5’-CATCCAGTGCACTGGTTGCTTG 
ATCAAGGAGAAGAATTTTGGG-3’ 
 
 
 
 
 
 
 
 
 
33 
2.3. Viruses 
Table 2.4. List of viruses 
Name Source 
Adeno-Cre-dsRed 
Adeno-mito-roGFP2-Grx1 
Adeno-mito-roGFP2-Orp1 
Vector BioLabs 
Gift from Dr. Tobias Dick 
Gift from Dr. Tobias Dick 
 
 
2.4. Antibodies 
Table 2.4. List of antibodies 
Name Source 
Anti-mouse IgG secondary antibody 
Anti-rabbit IgG microbeads 
Anti-rabbit IgG secondary antibody 
Mouse anti-CD31 antibody 
Mouse anti-V5 antibody 
Rabbit anti-ABCB10 mouse antibody 
(epitope FFDKTRTGELINRL) 
Rabbit anti-porin mouse antibody 
 
Cell Signaling 
Miltenyi Biotec 
Cell Signaling 
BD Pharmigen 
Invitrogen 
Research Genetics 
 
Abcam 
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2.5. Major instruments 
Table 2.5. List of major instruments 
Name Source 
Allegra 6R centrifuge 
Bench top centrifuge 
Incubator shaker 
Inverted fluorescence microscope 
Diode array spectrophotometer 
DNA gel electrophoresis system 
DSU spinning disk confocal microscope 
Gene Pulser Xcell 
Gentle MACS dissociator 
Imager LAS-4000 
Imaging film 
LSM 710-Live Duo scan 2-photon confocal 
microscope imaging system 
MACS cell separator 
NanoDrop Spectrophotometer 
PTC 200 Peltier thermal cycler 
Sorvall superspeed centrifuge 
SDS-PAGE gel and transfer system 
Slab dryer model 443 
Sonic dismembranator 550 
StepOnePlus real time PCR system 
Ultracentrifuge L8-70M 
Beckman 
Eppendorf 
New Brunswick Scientific 
Nikon 
Hewlett Packard 
Bio-Rad 
Olympus 
Bio-Rad 
Miltenyi Biotec 
Fuji 
Kodak 
Zeiss 
 
Miltenyi Biotec 
Thermo Scientific 
MJ Research 
Du Pont Instruments 
Invitrogen 
Bio-Rad 
Fischer Scientific 
Applied Biosystems 
Beckman 
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CHAPTER THREE 
METHODS 
 
3.1. Molecular cloning 
3.1.1. Confirmation of the construct pEF1α-ABCB10-V5-His  
The plasmid pEF1α-ABCB10-V5-His had already been constructed in the lab (Figure 
3.1.1.). To confirm this construct before using it for transfection, the plasmid underwent 
digestion by the restriction enzymes EcoRI and NotI. The digestion reaction system 
(10μl) contained 1μl 10x NE buffer 3, 500ng construct, 0.1μl 100x BSA, 0.5μl EcoRI, 
0.5μl NotI, and corresponding amount of ddH2O to fill the total volume. The reaction was 
performed at 37°C for 1h.  Then the digestion product was analyzed by DNA gel 
electrophoresis. Shortly, DNA samples were mixed with 10x loading buffer (made of 
3.9ml glycerol, 500μl 10% (w/v) SDS, 200μl 0.5M EDTA, 0.025g bromophenol blue, 
0.025g xylene cyanol, and H2O to get a final volume of 10ml) before running in the 1% 
ethidium bromide-stained agarose gel in TBE buffer (8.9mM Tris-HCl, 8.9mM Boric 
acid, 0.2mM EDTA). The gel ran at 90V for 20min at room temperature. Next, the gel 
was examined using UV light wavelength. Two bands were observed and the molecular 
sizes were around 6 kb and 2 kb, which indicated the linear vector pEF1α-V5-His and the 
ABCB10 fragment, respectively. The plasmid was also sequenced using the following 
primers: ABCB10 anti-sense 273-253, ABCB10 anti-sense 963-939, ABCB10 sense 827-
858, ABCB10 sense 1193-1225, and ABCB10 sense 1801-1827. 
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Figure 3.1.1. Plasmids used in the experiment. A) Original empty pEF1α-V5-His, B) 
Recombinant plasmid pEF1α-ABCB10-V5-His, C) plasmid pEGFP-N1. 
 
3.1.2. Point mutagenesis of the construct pEF1α-ABCB10-V5-His 
Seven ABCB10 mutants (G497A, K498R, G602V, G602D, E624Q, C547A and C675A) 
were created based on the plasmid pEF1α-ABCB10-V5-His using the QuikChange XL 
site-directed mutagenesis kit. Specifically, each PCR reaction system (50μl) contained 
5μl 10x reaction buffer, 50ng pEF1α-ABCB10-V5-His, 125ng forward primer, 125ng 
reverse primer, 1μl dNTP mix, 3μl QuikSolution, corresponding amount of ddH2O, and 
1μl Pfu Ultra HF DNA polymerase. The PCR cycle was as follows: 1) 95°C 1min, 2) 
95°C 50sec, 3) 60°C 50sec, 4) 68°C, 8.5min, 5) repeat 2) to 4) for 18 cycles, 6) 68°C, 
7min. The PCR product was treated with 1μl Dpn I restriction enzyme at 37°C for 1h to 
digest the non-mutated parental template, followed by ultracompetent cell transformation 
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and maxi-preparation. The mutants were verified by DNA sequencing using the 
following primers: ABCB10 anti-sense 273-253, ABCB10 anti-sense 963-939, ABCB10 
sense 827-858, ABCB10 sense 1193-1225, and ABCB10 sense 1801-1827. 
3.1.3. Transformation of competent E. coli and plasmid isolation 
50μl competent E. coli were thawed on ice before mixing with 10μl construct (containing 
10ng to 1μg) and incubation on ice for 30min. The mixture was then incubated in 42°C 
water bath for 30sec, followed by addition of 200μl antibiotic-free LB medium and 
shaking at 37°C for 1h. The E. coli-contained LB medium was spread on pre-warmed 
agarose LB plate supplemented with 100μg/ml ampicillin. The plate was incubated at 
37°C overnight. 
The transformed E. coli colonies appeared in the LB plate the next day. One colony was 
picked and incubated in 3ml (for mini-preparation) or 250ml (for maxi-preparation) 
ampicillin-supplemented LB medium by shaking at 37°C overnight. 
Mini- and Maxi-preparation of plasmids was performed using the Qiagen plasmid 
isolation kit. The yield of plasmids was measured using the Nanodrop spectrophotometer. 
 
3.2. Erythroid differentiation 
3.2.1 Mouse embryonic stem cell (ES cell) culture 
Frozen ABCB10+/- ES cells were thawed and plated in a 6-well plate that had been 
covered with 2.5x10
6
 MEF cells as a feeder layer one day before. Cells were cultured in 
the ES cell culture media, which was made of 250ml DMEM, 15ml mES serum, 3.125ml 
100x L-glutamine, 3.125ml 100x minimum essential media with non-essential amino 
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acids, 3.125ml 100x pyruvate, 3.125ml nucleotides, 2.2μl 100% β-mercaptoethanol, and 
31.25μl mLIF. Cells were cultured at 37°C in 5% CO2. 48-72h after plating, the 6-well 
was occupied by ball-like ES colonies. (Figure 3.2.1.) 
 
 
 
Figure 3.2.1. Embryonic stem cells. Ball-like ES cell colonies were formed on the 
feeder layer of MEF cells three days after thawing and plating of the ES cells (10x 
magnification). 
 
3.2.2. Embryonic bodies (EBs) formation  
ES colonies were washed with non-Ca
2+
/Mg
2+
 PBS and trypsinized with 0.25% trypsin. 
1min later warm media was added to inactivate trypsin and cells were triturated 3-4 times 
to be dispersed into individual ones. Cells were re-suspended in EB differentiation media, 
which was made of 82ml IMDM, 15ml mEB serum, 1ml 100x glutamine, 300μl 1:76 
diluted MTG, 5ml PFHM, and 500μl 30mg/ml transferin. After that cells sat in the 
gelatin-coated well for 20min to eliminate MEFs. The collected ES cells were 
 
 
 
 
40 
electroporated with plasmids (see transfection in the methods chapter) or directly went to 
the EBs formation process without electroporation. Then, 3x10
4
 individual ES cells were 
cultured in the IMDM media using the Costar low-attachment plates. EBs were formed 5-
6 days after culture at 37°C in 5%CO2 (Figure 3.2.2.).  
 
 
 
Figure 3.2.2. Embryonic bodies. Embryonic bodies formed at day 4, 5 and 6 after 
electroporation (20x magnification). pEGFP-N1 was co-electroporated. Electroporation 
efficiency was confirmed by observing green fluorescence emission (lower panels). 
 
3.2.3. Formation of burst forming units of erythroid (BFU-E) 
EBs were collected by rotating the 6-well plate with hands and locating them in the 
middle of the well. The collected EBs with IMDM media was transferred into a 50ml 
Falcon tube and waited for 15min for precipitation. IMDM media was aspirated and PBS 
was added to wash EBs, followed by trypsinization at 37°C for 2min. Afterwards, IMDM 
was added to inactivate trypsin and EBs were triturated up and down for several times, 
followed by passing through 40 micron strainer for dispersion into individual cells. Cells 
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were centrifuged at 1000rpm for 5min and re-suspended with IMDM. Then, they were 
mixed with the semi-solid media MethoCult GFM3444 and plated on the 6-well plate 
after passing through an 18 guage needle. Each well was plated with 7x10
4
 cells in 200μl 
IMDM mixed with 1.5ml semi-solid media MethoCult GFM3444. Cells were cultured for 
5 days at 37°C in 5% CO2 before counting the BFU-E colonies.  
 
3.3. Cell transfection 
3.3.1. HEK293 cell culture and transfection 
HEK293 cells were thawed and cultured in DMEM with 10% FBS and supplemented 
100x penicillin/streptomycin at 37°C in 5% CO2. Transfection was conducted using the 
calcium-phosphate transfection method. In detail, the calcium buffer was made of 
500mM CaCl2 and 100mM BES with a pH value of 6.95. Phosphate buffers were made 
of 50mM NaCl, 50mM BES, 0.75mM Na2HPO4, 0.75mM NaH2PO4. Distinct pH values 
(6.50, 6.55, 6.6, through 7.4) were set for each phosphate buffer. All buffers were 
prepared in milliQ water and passed through a 0.22μm filter. To test transfection 
efficiency of these buffers, HEK293 cells were washed with PBS, typsinized, and plated 
in four 6-well plates with a confluence of 5x10
5
 cells/well one day before transfection. 
On the testing day, transfection solutions were prepared in 19 Eppendorf tubes. 
Specifically, for each tube, a total of 1μg plasmids (pEF1α-ABCB10-V5-His or its 
mutants: pEGFP-N1= 5:1) were added in milliQ H2O to make a total volume of 50μl, 
followed by mixing with 50μl calcium buffer and 100μl phosphate buffer that has a 
specific pH value. Phosphate buffers with distinct pH values were added in different 
 
 
 
 
42 
Eppendorf tubes, respectively. These 19 transfection solutions were then added into 19 
wells of the four 6-well plates that had been plated with HEK293 cells one day before. 
48h later, transfection efficiency in each well was examined by checking green 
fluorescence-emitting HEK293 cells under fluorescence microscopy. The phosphate 
buffer producing optimal transfection efficiency that was measured as percentage of GFP 
positive cells over the total cells was used in the subsequent experiments. The prepared 
calcium and phosphate buffers could be stored at 4°C.  
Once the optimal buffers for transfection had been determined, a huge amount of 
HEK293 cells could then be transfected. In detail, three days before transfection, 
HEK293 cells were washed with PBS, trypsinized, and plated into 150mm x 25mm 
Corining dishes. Each dish contained 3x10
6
 cells in 18ml media. Specifically, a total of 
40μg plasmids (pEF1α-ABCB10-V5-His or its mutants: pEGFP-N1= 5:1) were put in 
milliQ H2O to make a total volume of 500μl, followed by addition of 500μl calcium 
buffer and 1ml optimal phosphate buffer. The solution was mixed vigorously for 1min by 
making bubbles, stood rest for 15min and mixed vigorously again for 1min before being 
added into HEK293 cells in 150mm dishes. The media was replaced with fresh one on 
the next day. 48h later, transfection efficiency was examined by checking green 
fluorescence-emitting cells under fluorescent microscopy. Typically, it was around 90-
100%. 
3.3.2. Electroporation of ES cells 
Dispersed ES cells were re-suspended in 100μl Opti-MEM media and mixed with 5μg 
pEF1α-ABCB10-V5-His (or the empty vector pEF1α-V5-His) and 5μg pEGFP-N1 (1:1). 
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The mixture was added into the 0.2cm cuvette and was placed in the ShockPod with lid 
closed. Electroporation was carried out on the Gene Pulser Xcell and the pulse setting 
was 220V, 950μF, 1000Ω and 2mm. 500μl IMDM was added into the cuvette 
immediately after pulsing. The cells were cultured for EBs formation and transfection 
efficiency was verified several days later by examining the green fluorescence-emitting 
EBs under fluorescence microscopy. 
 
3.4. Isolation of mitochondria 
Mitochondrial isolation was performed 48h after transfection of HEK293 cells [89]. In 
detail, cells were washed with ice-cold PBS, scraped and collected in 50ml tubes (one 
tube collected three 150mm dishes of confluent HEK293 cells with 45ml PBS), 
centrifuged at 600g for 10min at 4°C, and re-suspended in ice-cold IBc buffer (made of 
10mM Tris-MOPS, 1mM EGTA/Tris, 200mM sucrose, and water, pH 7.4) (3ml IBc was 
added for the cell pellets in one 50ml tube). The cell suspension was stroked with a 
Teflon pestle in a 2ml glass potter for 35 times. The homogenate was centrifuged at 600g 
for 10min at 4°C. The supernatant was collected and re-centrifuged for 2 to 3 times until 
there was very few cell debris left at the bottom. The supernatant was then divided, put 
into 1.5ml Eppendorf tubes and centrifuged at 7,000g for 10min at 4°C. Afterwards, the 
supernatant was discarded and the pellets (mitochondria) were re-suspended in 50μl ice-
cold IBc buffer. Protease inhibitors were added and mitochondria could be stored at -
80°C. 
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3.5. Acquisition of sub-mitochondrial particles (SMPs) 
Mitochondria were mixed with 1ml TS buffer (made of 10mM Tris HCl and 250mM 
sucrose, pH 7.4), put into Beckman 13x51mm Ultra-Clear tubes and sonicated on ice 
using 550 Sonic Dismembrator. Sonication was performed at 5% output, 10sec for 3 
times with 20sec intervals. The sonication solution was ultra-centrifuged at 100,000g, for 
40min, at 4°C [90]. The supernatant was discarded and the pellets (SMPs) were 
resuspended with photolabeling buffer (made of 2mM ouabain, 0.1mM EGTA, 3mM 
MgCl2, and 40mM Tris-HCl, pH 7.5) [91], transferred into Eppendorf tubes, and assayed 
for protein concentrations. 
 
3.6. Photolabeling of ABCB10 by 8-azido-ATP 
80μg of SMPs were incubated on ice for 5min with 50µM 8-azido-ATP [γ] biotin or [α-
32
P] 8-azido-ATP (specific activity: 7.0Ci/mmol) in the presence or absence of other 
reagents, such as dALA, GSH, GSSG, or different nucleotides. After that, the ice-cold 
reactions were irradiated with UV light (254nm in wavelength) for another 5min. The 
total reaction volume was 25μl [92, 93]. 
 
3.7. Immunoprecipitation with anti-V5 antibody 
After UV irradiation, each sample was mixed with 200μl RIPA (made of 50mM Tris-HCl 
(pH 7.5), 150mM NaCl, 1mM EDTA, 1% NP-40, 0.1% SDS, 0.5% sodium 
deoxycholate) buffer with protease inhibitors and put on ice for 30min to solubilize the 
mitochondrial membranes. Then the samples were centrifuged at 16,000g for 30min at 
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4°C. The supernatant was collected and mixed with 30μl PBS-washed anti-V5 agarose 
affinity gel beads. The mixture was rotated at 4°C overnight. Then the samples were spun 
down at 5,000rpm for 5min at 4°C. The supernatant was discarded and the ABCB10-
bound anti-V5 agarose affinity gel beads were washed 4 times with 500μl RIPA buffer. 
After the final wash, 10μl RIPA buffer above the beads was left, followed by mixing with 
additional RIPA buffer and 6x SDS sample buffer (made of 375mM Tris-HCl pH 6.8, 6% 
SDS, 48% glycerol, 9% β-MeSH, 0.03% bromophenol) to make a final volume of 50μl 
and heated. Proteins were denatured and released from beads by heating at 98°C for 
10min. Finally samples were spun down at 5,000rpm for 5min. After that beads were left 
in the bottom and the denatured proteins in supernatants were collected for SDS-PAGE.  
 
3.8. Western blot and autoradiography 
For SDS-PAGE analysis, 20μl samples were loaded in each lane of the NuPAGE 10% 
Bis-Tris precast mini gel. Electrophoresis was performed at 180V for 1h in MOPS SDS-
running buffer using the Invitrogen XCell electrophoresis system. For transfer of proteins 
from the gel onto the PVDF membrane, a blot sandwich was prepared from bottom to top 
as follows: 1) two pieces of transfer buffer-soaked sponges, 2) three pieces of transfer 
buffer-soaked Whatman filter paper, 3) PVDF membrane that had been soaked with 
methanol for 1min, 4) mini gel, 5) three pieces of transfer buffer-soaked Whatman filter 
paper, 6) two pieces of transfer buffer-soaked sponges. The sandwich was tightly placed 
in the Invitrogen XCell blot module and soaked with the Invitrogen transfer buffer with 
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the PVDF membrane facing the anode. The transfer was performed at 5V overnight in the 
cold room.  
For detection of ABCB10 protein or detection of photolabeled 8-azido-ATP [γ] biotin, 
the PVDF membranes were first blocked with the blocking buffer (made of PBS, 0.1% 
(v/v) tween-20, 2% milk powder) by gentle shaking for 1h at room temperature. The 
membrane for ABCB10 detection was then incubated with primary antibody anti-
ABCB10 (1:2,000) in the blocking buffer by shaking for 1h at room temperature. The 
membrane for photolabeled 8-azido-ATP [γ] detection was incubated with horseradish 
peroxidase-conjugated ExtrAvidin (ExtrAvidin-HRP) (1:1,000) in the blocking buffer by 
gentle shaking for 1h at room temperature. Membranes were followed with PBST buffer 
(made of PBS and 0.1% (v/v) tween-20) by gentle shaking for 3 times (10min each time). 
The ExtrAvidin-HRP-incubated membrane was ready for signal detection. The anti-
ABCB10-incubated membrane was incubated with horseradish peroxidase-conjugated 
anti-rabbit secondary antibody (1:10,000) in PBST by shaking for 1h at room 
temperature, followed by washing with PBST by gentle shaking for 3 times (10min each 
time).  
For enhanced chemiluminescence (ECL) signal detection, 500μl stable peroxide buffer 
was mixed with 500μl luminol/enhancer solution. The membranes were soaked with the 
mixed solution for 15 to 30sec. The chemiluminescent signal was detected using Fuji 
LAS-4000 biomolecular imager.  
For detection of radioactivity of photolabeled [α-32P] 8-azido-ATP, the mini-gel was 
dried in Bio-Rad Model 443 slab dryer at 60°C for 4h. Then in the dark room, the dry gel 
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was fixed on a Kodak x-ray film and placed in an autoradiography cassette for 5 to 6 
days.  
 
3.9. Glutathionylation of ABCB10 
100μg SMPs from cells overexpressing ABCB10-V5 were incubated in the RIPA buffer 
together with 1mM biotin-labeled GSH, 100mM Tris-HCl (pH 7.5), and 100x protease 
inhibitor at room temperature for 4h. Then the samples were centrifuged at 16,000g for 
30min at 4°C. The supernatant was collected for immunoprecipitation with anti-V5 
antibody, followed by SDS-PAGE. The ABCB10-bound biotin-labeled GSH was 
detected by ExtrAvidin-HRP using Fuji LAS-4000 biomolecular imager. 
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CHAPTER FOUR 
ROLE OF ABCB10 IN ERYTHROID DIFFERENTIATION FROM ES CELLS 
 
4.1. Background 
Erythropoiesis is the process of red blood cell maturation. It starts with pluripotent ES 
cells and is followed by differentiation into multipotent human hematopoietic stem cells 
(HSC). HSC can branch out into lymphocytes or differentiate further into common 
myeloid progenitors (CMP), which can divide into granulocytes or 
megakaryocytes/erythroid progenitors (MEP). MEP give rise to either megakaryocytes or 
burst forming units-erythroid (BFU-E). The latter is committed to red blood cell 
development by passing through the stages of colony forming units-erythroid (CFU-E), 
pro-erythroblasts, erythroblasts, normoblasts, reticulocytes, and erythrocytes (mature red 
blood cells). Erythroid maturation is mainly regulated by the zinc transcription factor 
GATA binding protein 1 (GATA-1) [94]. It is involved in the up-regulation of globin 
gene expression during erythroid maturation [95]. In addition, many other erythroid 
differentiation-associated genes are also downstream targets of GATA-1, including 
porphobilinogen deaminase, ferritin light chain and ABCB10 [15].  
ABCB10 is required for heme biosynthesis [15], although its mechanism is not 
completely elucidated. There are some other mitochondrial ABC transporters, such as 
ABCB6 and 7, that could facilitate heme biosynthesis and their expressions are more 
significant in hematopoietic stem cells (HSCs) than in non-HSCs [3, 53, 96]. Erythroid 
differentiation requires increased heme biosynthesis [97]. Therefore it is hypothesized 
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that ABCB10 is an enhancer of erythroid differentiation. A previous experiment showed 
that silencing of ABCB10 in erythroid leukemia K562 cells resulted in decreased 
erythrocytes production, which was confirmed either by decreased expression of 
erythroid marker CD71 and GPA/Ter119 or by visualization of decreased hemoglobin 
[69]. This shows that ABCB10 is essential for terminal red blood cell development. 
Based on this, we therefore asked whether over-expression of ABCB10 in ES cells could 
have an effect on erythroid differentiation. 
 
4.2. Results 
Transparent ES colonies were formed 3 days after placing of ES cells on the feeding 
MEF cell layer. Each colony originated from one ES cell. The colonies were then 
dispersed into single cells. A portion of the dispersed cells were used for genotyping and 
they were confirmed to be heterozygous ABCB10. Other cells did or did not undergo 
electroporation before they were cultured to differentiate into EBs. The EBs originating 
from electroporated cells emitted green fluorescence under fluorescent microscopy, 
which suggested success of electroporation and expression of the genes carried by the 
plasmids. EBs were then dispersed into individual cells and erythroid differentiation was 
induced to form BFU-E colonies. The number of BFU-E colonies was significantly 
higher in those differentiating from the ES cells electroporated with ABCB10-carried 
plasmids pEF1α-ABCB10-V5-His (BFU-E colony number: 1132 + 212, mean + standard 
deviation) than those from the non-electroporated ES cells (453 + 61) or from the ES 
cells electroporated with the empty vectors pEF1α-ABCB10-V5-His (571 + 52). This 
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result shows that over-expression of ABCB10 in the ABCB10+/- heterozygous ES cells 
increased erythroid differentiation. 
   
                 No electroporation                             pEF1α-V5-His                     pEF1α-ABCB10-V5-His 
                                                                             & pEGFP-N1                                & pEGFP-N1 
A 
   
B 
Figure 4.2. BFU-E colonies on day 5 of erythroid differentiation. A) Typical BFU-E 
colonies differentiated from ES cells electroporated with no vectors (left), pEF1α-V5-His 
and pEGFP-N1 (middle), and pEF1α-ABCB10-V5-His and pEGFP-N1 (right) (10x 
magnification). B) Numbers of BFU-E colonies are 453 + 61, 571 + 52, and 1132 + 212 
for these conditions, respectively (data are shown as mean + standard deviation, n=3, 
*p<0.05, t-test). 
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CHAPTER FIVE 
PHOTOLABELING OF ABCB10 BY 8-AZIDO-ATP 
 
5.1. Background 
In order to determine the mechanism by which ABCB10 facilitates heme biosynthesis, 
protects mitochondria from oxidative stress and stimulates erythroid differentiation, it is 
important to know the basic function of ABCB10. For ATP binding cassette (ABC) 
transporters, there is a basal ATP binding and hydrolysis rate even in the absence of their 
substrates [98]. However it is difficult to detect ATP binding by ABCB10 by using 
natural ATP. The binding is in dynamic stability, which means that the already bound 
ATP is always replaced with other ATP, or if there is ATP hydrolysis, ATP becomes 
ADP which is later replaced with ATP. Therefore the first-bound ATP will be released 
after a series of steps during the experiment and cannot be detected. Using the 
synthesized chemical 8-azido-ATP (Figure 5.1.1.), an analog of natural ATP, can solve 
this problem. Besides its structural similarity to ATP, 8-azido-ATP possesses an 
additional photoactive azido group in the position 8 of its adenine ring. Therefore 8-
azido-ATP is also an aryl azide. Upon photoactivation by UV light, the chemically inert 
azido group turns into a highly reactive nitrene group which can react with its nearby 
chemical structures through double bonds, insertion into the C-H and N-H sites, or ring 
expansion to react as a nucleophile with primary amines (Figure 5.1.2.A.). In this way, 
the aryl group is permanently tagged with the chemical structure that has reacted with the 
nitrene group. For testing the 8-azido-ATP binding by ABCB10, after the binding of 8-
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azido-ATP with NBD, UV light is used to photoactivate the binding reaction, which 
causes the conversion of the azido group into the nitrene group. The nitrene group was 
inserted into the above-mentioned chemical structures of NBD and helps ATP 
permanently tagged with ABCB10. This process is also called photolabeling of the NBD 
by 8-azido-ATP. In order to detect the tagged 8-azido-ATP, it is labeled either with a 
biotin group in the γ-phosphate or with a radioactive α-phosphate (α-32P). These two 
formed chemicals are called 8-azido-ATP [γ] biotin and [α-32P] 8-azido-ATP, 
respectively (Figure 5.1.1.). Detection of the biotin group is dependent upon both the 8-
azido-ATP binding and hydrolysis. Increased binding could lead to increased biotin 
detection while increased hydrolysis could lead to decreased biotin detection, as the 
biotin-labeled γ-phosphate is released during hydrolysis. For [α-32P] 8-azido-ATP, 
increased binding could lead to increased radioactivity detection while increased 
hydrolysis will not affect this detection since the α-phosphate is not released during 
hydrolysis. 
When designing the experiment, it is important to consider the fact that NBDs of 
ABCB10 is inside the mitochondrial matrix. Although there is adenine nucleotide 
translocases (ANT) which transport ATP across the mitochondrial inner membrane, it 
usually exports synthesized ATP from the mitochondria to the cytosol. Therefore 
exogenous 8-azido-ATP cannot enter mitochondria and it is hard for NBDs in the intact 
mitochondria to touch them.  Sonication is performed to break mitochondria outer and 
inner membranes. A lot of small vesicles can be formed by re-sealing the broken 
mitochondrial inner membranes. Most of them are inside-out vesicles because the base of 
 
 
 
 
53 
the mitochondrial cristae is the site that is mostly easily broken after sonication and it is 
easy for cristae to re-seal those small broken gaps and form inside-out vesicles. In this 
way, NBDs of ABCB10 localized in mitochondrial cristae are exposed [99] (Figure 
5.1.3.). 
 
                       8-azido-ATP 
            8-azido-ATP [γ] biotin 
                                          [α-32P] 8-azido-ATP  
 
 
Figure 5.1.1. 8-azido-ATP molecules. The azide N3 (in blue) is on the position 8 of the 
adenine ring. Top: 8-azido-ATP, middle: 8-azido-ATP [γ] biotin, bottom: [α-32P] 8-azido-
ATP (in red). 
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A 
 
 
              
B 
 
 
Figure 5.1.2. Pathways of chemical reactions for photolabeling with aryl azide 
(Thermo Scientific Tech Tip No.11). A) Upon UV light exposure, the azido group 
(N=N
+
=N
-
) is converted into the nitrene gropu (N:), which tags bound proteins through 
double bounds, insertion into C-H and N-H sites, or ring expansion to react as a 
nucleophile. B) The conversion of the azido group (N3) into the nitrene group (N:) in 8-
azido-ATP exposed to UV light. 
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Figure 5.1.3. Acquisition of sub-mitochondrial particles (SMPs) from intact 
mitochondria. Mitochondria undergo sonication. The mitochondrial inner membrane 
forms SMPs, most of which are inside-out vesicles. The nucleotide binding domains 
(NBDs) of ABCB10 are exposed in this way. Ovals: SMPs; circles: vesicles made of 
outer membrane; red rectangles: NBDs of ABCB10; violet squares: substances inside 
matrix; green triangles: substances in the inter-membrane space. 
 
Studies performed in other ABC proteins have shown that the Walker A motif binds to 
ATP by the interaction of the oxygen atoms of the β- and γ-phosphates with the 
conserved amino acids lysine and glycine [32, 39]. The conserved glutamate residue in 
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the end of the Walker B motif is the catalytic base for ATP hydrolysis [37, 100]. The 
second glycine residue in the C-loop motif also interacts with the γ-phosphates of ATP 
and the mutation of this residue decreases ATP hydrolysis in other ABC proteins [43, 
101]. However, the importance of these conserved residues in ATP binding and 
hydrolysis of ABCB10 has not been described before.  
 
5.2. Results 
5.2.1. Photolabeling of ABCB10 with 8-azido-ATP [γ] biotin 
48h after co-transfection of HEK293 cells with the plasmids p-EF1α-ABCB10-V5-His 
and pEGFP-N1, about 90% cells were transfected, which was determined by green 
fluorescence emission under fluorescent microscopy (Figure 5.2.1.1.A.). The V5 peptide-
tagged ABCB10 protein was over-expressed in HEK293 cells and was detected in the 
mitochondrial fraction (Figure 5.2.1.1.B.). Sub-mitochondrial particles (SMPs) were 
generated by sonication of isolated mitochondria from cells overexpressing ABCB10-V5. 
ABCB10 was successfully detected in SMPs by Western blot using the antibody against 
either ABCB10 or V5 tag (Figure 5.2.1.1.C.). This result suggests that SMP preparation 
did not promote ABCB10 solubilization, degradation or significant C-terminal cleavage. 
Thus, ABCB10 was stable under these conditions. Furthermore, SMPs could be used to 
determine basal ATP binding and hydrolysis activity, which was defined as the activity of 
ABC proteins without a significant or very minor presence of their substrates. 
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Figure 5.2.1.1. Over-expression of ABCB10-V5 in intact mitochondria and SMPs.  
A) HEK293 cells at 48h after transfection with pEF1α-ABCB10-V5-His and pEGFP-N1. 
About 90% of cells expressed GFP (left: bright field, right: under fluorescent microcsopy, 
20x magnification). B) Overexpression of murine ABCB10-V5 in HEK293 cells. 20ug of 
proteins from total cell lysate, isolated mitochondria and cytosol were loaded in each 
lane, respectively. ABCB10 (around 65kD) was detected using anti-V5 antibody 
(1:5000). The mitochondria outer membrane protein porin was used as a control for 
mitochondrial fraction. C) ABCB10-V5 overexpression in sub-mitochondrial particles 
(SMPs) obtained from isolated mitochondria from the control HEK293 cells transfected 
with empty vector pEF1α-V5-His and the HEK293 cells transfected with pEF1α-
ABCB10-V5-His. ABCB10 was detected by Western blot using anti-ABCB10 polyclonal 
antibody (1:2000, showing a specific ABCB10 band and three other unspecific ones in 
the right lane) (left panel) and anti-V5 antibody (1:5000) (right panel). The ABCB10-V5 
bands are indicated by arrows.  
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 The basal ATP binding capacity of ABCB10 was determined by incubating SMPs with 
an ATP analog, 8-azido-ATP [γ] biotin, followed by UV light irradiation. As the biotin 
group was located in the γ-phosphate position, ATP hydrolysis activity of ABCB10 was 
able to remove the biotin label. Therefore, the biotin presence in ABCB10 immuno-
purified from SMPs using the anti-V5 agarose gel beads was a balance of ATP binding 
and hydrolysis activity of ABCB10. The biotin signal was detected by observing a band 
with a molecular weight around 65kD in Western blot acquired from the use of the 
horseradish peroxidase tagged avidin (ExtrAvidin-HRP). The other portion of the same 
immunoprecipitation products was blotted with anti-ABCB10 antibody after its running 
on the other SDS-PAGE gel and a band with the same molecular weight was observed 
afterwards. These results show the success of photolabeling of ABCB10 with 8-azido-
ATP [γ] biotin (Figure 5.2.1.2.A.).  
This photolabeling detected by the biotin label did not occur if the intact mitochondria 
with no sonication were incubated with 8-azido-ATP [γ] biotin followed by UV irridation 
(Figure 5.2.1.2.B.). This result further confirms that NBDs of ABCB10 is facing the 
mitochondrial matrix and do not contact the exogenous 8-azido-ATP [γ] biotin if they are 
not exposed outside. Only NBDs on the inside-out SMPs could be photolabeled. 
Therefore SMPs instead of intact mitochondria should be used for the photolabeling 
experiment.  
For most ABC transporters, interaction of Mg
2+
 with the Walker A and Walker B motifs 
coordinates ATP binding to NBDs [33, 102], while in some other ABC transporters, it 
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shows that this binding is Mg
2+
-independent [103, 104]. Here for ABCB10, Mg
2+
 did not 
enhance the 8-azido-ATP [γ] biotin binding by NBDs (Figure 5.2.1.2.C.). 
It is also shown that the detected biotin signal in ABCB10 increased in a dose-dependent 
manner and it saturated at higher 8-azido-ATP [γ] biotin concentrations. This dose-
dependent increase fit a Michaelis-Menten curve with a Km value of 128μM 8-Azido-
ATP. The bands detected by anti-ABCB10 antibody suggested that the same amounts of 
samples were loaded in each lane and thus the difference in the biotin signal intensities 
was exclusively caused by the different extents of photolabeling by 8-azido-ATP [γ] 
biotin (Figure 5.2.1.2.D.). 
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Figure 5.2.1.2. Photolabeling of ABCB10 by 8-azido-ATP [γ] biotin. A) SMPs (80µg 
protein) from control pEF1α-V5-His (lane 1) or pEF1α-ABCB10-V5-His (lane 2, 3 and 
4) transfected cells were incubated with 0 or 50uM of 8-azido-ATP [γ] biotin on ice for 
5min, treated with (+) or without (-) UV light for another 5min, followed by IP with anti-
V5 agarose affinity gel beads. After IP, the same amounts of samples ran on two gels and 
were blotted with ExtrAvidin-HRP (1:1000) or anti-ABCme (1:2000), respectively. B) 
ABCB10-V5-contained SMPs and intact mitochondria were tested for the 8-azido-ATP 
[γ] photolabeling. The photolabeling occurred only when SMPs were used. C) The 
presence of Mg
2+
, an ATP binding facilitator in other ABC transporter proteins, did not 
increase the 8-azido-ATP [γ] biotin photolabeling in ABCB10. D) Representative 
Western blot shows that the 8-azido-ATP [γ] biotin photolabeling was dose-dependent 
and the Michaelis-Menten curve shows a Km value of 128µM. Three independent 
experiments were performed and data on the graph are shown as mean ± SEM.  
 
5.2.2. Competition of 8-azido-ATP [γ] photolabeling with nucleotides 
Photolabeling by 8-azido-ATP [γ] biotin was performed in the presence of increasing 
concentrations of natural ATP and it was found that the biotin signal in ABCB10 was 
decreased (Figure 5.2.2.A.). In a typical ATP hydrolysis cycle, the bound ATP is 
hydrolyzed and γ-phosphate is released. At this moment ADP occupies the ATP binding 
site and later it is replaced by another ATP molecule for the hydrolysis cycle to proceed. 
Thus, ADP, as in other ATPase proteins, should be able to compete with ATP for 
binding. We confirmed that ADP could also compete with 8-azido-ATP [γ] biotin for 
binding to a similar extent as ATP (Figure 5.2.2.B.). These data confirmed that the 8-
azido-ATP [γ] biotin binding by the ABCB10 NBDs was specific. AMP, unlike ATP and 
ADP, did not compete the binding and thus did not change the biotin signal detected in 
ABCB10 (Figure 5.2.2.B.). Reports have shown that other nucleotides, such as GTP, 
CTP and TTP, can also compete with ATP for binding by ABC transporters [105]. In 
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ABCB10, the competition by GTP, CTP and TTP also existed. However their 
competition effects were not as strong as ATP and ADP (Figure 5.2.2.B.). This result 
shows that ATP is the main nucleotide bound and hydrolyzed by ABCB10 to provide the 
energy that is required for the transport of substrates. 
 
 
 
 
 
A 
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Figure 5.2.2. Competition of 8-azido-ATP photolabeling with nucleotides. A) 
Increasing concentrations of natural ATP decreased 8-azido-ATP [γ] biotin signal 
detected with Extravidin-HRP, indicating that the 8-azido-ATP binding to ABCB10 is 
specific. The bar graph shows the ExtrAvidin-HRP signal intensities normalized with that 
in no ATP treatment. Three independent experiments were performed and data are shown 
as mean + SEM. *p<0.05 vs. the signal in no ATP treatment (t-test). B) A representative 
Western blot analysis and the bar graph show that ATP and ADP had the strongest 
competition with 8-azido-ATP [γ] biotin for binding to ABCB10. GTP, CTP and TTP 
could also compete with 8-azido-ATP [γ] biotin for ABCB10 binding but to a lower 
extent. AMP did not compete for the binding. Three independent experiments were 
performed and data are shown as mean + SEM. *p<0.05 vs. the signal without 
nucleotides treatment (t-test). 
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5.2.3. The effects of mutations on 8-azido- ATP [γ] photolabeling 
Several conserved amino acid residues in NBDs of ABCB10 were mutated and their 
effects on photolabeling by 8-azido-ATP [γ] biotin were checked. These mutations have 
been reported to affect the ATP binding and/or hydrolysis in other ABC transporters. 
They include the mutations in the conserved glycine and lysine residues of the Walker A 
motif (conversion of GPSGSGKST to GPSGSAKST, and conversion of GPSGSGKST to 
GPSGSGRST) [32, 39, 40]. These set of mutations primarily affect ATP binding and 
concomitantly hydrolysis. Another set of mutations were performed in the conserved 
glycine of the C-loop motif (conversion of LSGGQ to LSGVQ, and conversion of 
LSGGQ to LSGDQ) [43, 101, 106] and in the conserved glutamate in the end of the 
Walker B motif (conversion of ILLLDE to ILLLDQ). These set of mutations affected 
ATP hydrolysis activity, but not ATP binding in other ABC proteins [37, 107, 108]. The 
data show that the set of mutations in the Walker A motif caused nearly 50% decrease in 
the biotin signal, which could be explained by the reduced 8-azido-ATP [γ] biotin 
binding (Figures 5.2.3). Other mutations in the C-loop motif or in the Walker B motif, 
which have been shown to affect ATP hydrolysis but not binding in other ABC proteins, 
increased ABCB10 photo-labeling affinity by 50-100% (Figure 5.2.3.).This increase was 
expected, as inhibition of 8-azido-ATP [γ] biotin hydrolysis would prevent the release of 
the γ-phosphate containing the biotin group. Thus, the conserved residues in NBD of 
ABCB10 have the same role as those existing in other common ABC proteins. Indeed, a 
recent study confirmed that the same mutation of glutamate to glutamine in the end of the 
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Walker B motif in the purified and reconstituted human ABCB10 protein completely 
inhibits ATP hydrolysis activity, which was measured using a different approach [67]. 
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Figure 5.2.3. Effects of mutations in NBDs on photolabeling. A) Representative 
Western blot analysis of 8-azido-ATP [γ] photolabeling signals from SMPs of HEK293 
cells transfected with the wild type ABCB10 and different mutants (E624Q in the end of 
Walker B; G497A in Walker A; K498R in Walker A; G602V in Loop C; G602D in Loop 
C). On the other gel, the same amount of sample was blotted using a polyclonal ABCB10 
antibody. B) ExtrAvidin-HRP signal intensity was normalized by the amount of ABCB10 
protein, considering that ABCB10 expression levels were different in different mutants. 
The bar graph shows the relative ExtrAvidin-HRP signal intensities compared with that 
in the wild type ABCB10. Mutations in Walker A (G497A and K498R) decreased the 
relative Extravidin-HRP signal by ~40%, while mutations in Walker B (E624Q) and 
Loop C (G602V and G602D) increased the signal. Three independent experiments were 
performed and data are shown as mean + SEM. *p<0.05 vs. the signal in wt ABCB10 (t-
test). 
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CHAPTER SIX 
TEST OF POTENTIAL SUBSTRATES AND/OR MODULATORS OF ABCB10 
 
6.1. Background 
ABC transporters usually show a basal rate of ATP hydrolysis, while in the presence of a 
substrate, this rate can be elevated by many folds [98]. For example, the ATPase activity 
of MDR1, an ABC transporter that belongs to the same sub-family (sub-family ABCB) as 
ABCB10 and is responsible for drug resistances, is greatly increased when in the 
presence of its substrates like verapamil, 5-flurouracil, vinblastine, calcein AM, 
valinomycin and Rhodamine 123 [39, 109, 110]. The binding of peptides to the TMDs of 
TAP/ABCB2, which also belongs to sub-family ABCB, stimulates the TAP-specific 
ATPase activity [111, 112]. After depletion of cholesterol, the endogenous substrate of 
ABCA3, which is an ABC transporter that belongs to sub-family ABCA and is 
responsible for transport of lipid components of pulmonary surfactant, the ATPase 
activity is strongly suppressed [113]. These studies demonstrate that initial substrate-
binding by the TMD directly correlates with the ATP hydrolysis by NBD. Along with the 
increased ATP hydrolysis, the ATP binding capacity is also elevated in the presence of 
substrates, as shown in some ABC transporters [30, 114]. The increased ATP hydrolysis 
in the presence of substrates is due to the increased energy consumption by the transport 
process. This theory can be utilized to test whether certain molecules are potential 
substrates and/or modulators of ABCB10. Considering that two physiological functions 
have been figured out in ABCB10, which are facilitation of heme biosynthesis and 
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prevention against oxidative stress damage, the heme biosynthesis precursor dALA and 
the redox regulation couple GSH/GSSG were examined to see whether they could 
modulate ATP binding and hydrolysis by ABCB10.  
 
6.2. Results 
6.2.1. The effect of dALA on photolabeling of ABCB10 by 8-azido-ATP [γ] biotin  
Since ABCB10 is known to be essential for hemoglobin production and erythroid 
differentiation [15, 71, 69], it could potentially mediate the transport of the heme 
biosynthesis intermediates across the mitochondrial inner membrane. Given that the 
mitochondrial exporter of the heme precursor delta-aminolevulinic acid (dALA) has not 
been described yet, it was hypothesized that ABCB10 could mediate its export. This 
hypothesis is recently supported by the finding that dALA supplementation could rescue 
some defects caused by partial ABCB10 down-regulation in cardiac cell lines [115]. 
However this hypothesis is not consistent with another report showing that ABCB10 KO 
erythroid cells accumulate PPIX [73]. Since PPIX synthesis requires dALA export from 
mitochondria, the accumulation of PPIX demonstrates that dALA export occurs normally 
in ABCB10 KO erythroid cells. To reconcile these findings, dALA was tested for 8-
azido-ATP [γ] biotin photolabeling to examine whether it could activate ABCB10 ATP 
hydrolysis and thus decrease the biotin labeling in a dose-dependent manner. It was found 
in the experiment that increasing concentrations of dALA caused a decrease in the biotin 
signal, but only statistically significant at a very high concentration of 5mM, which was 
far beyond the physiological concentration range of dALA inside mitochondria (Figure 
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6.2.1.). This result suggests that dALA in the physiological concentration range does not 
stimulates ATP hydrolysis by ABCB10 and it is not a candidate of transported substrate 
of ABCB10. 
 
 
A 
 
 
 
B 
 
Figure 6.2.1. Effect of dALA on photolabeling of ABCB10 by 8-azido-ATP [γ] 
biotin. A) 5mM of δ-aminolevulinic acid (dALA) decreased the biotin signal during the 
photolabeling with ABCB10 by 8-azido-ATP [γ] biotin. A representative Western blot 
analysis is shown. B) The bar graph shows the ExtrAvidin signal intensities normalized 
with that without dALA treatment. Three independent experiments were performed and 
data are shown as mean + SEM. *p<0.05 vs. the signal in 0mM dALA treatment (t-test). 
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6.2.2. The effects of GSH and GSSG on photolabeling of ABCB10 by 8-azido-ATP 
[γ] biotin and [α-32P] 8-azido-ATP  
Previous research has shown that ABCB10 mediates protection of mitochondria from an 
acute increase in oxidative damage, as a result of 10min ischemia followed by 20min 
reperfusion in heart [78]. On the other hand, the mitochondrial GSH/GSSG ratio level 
(reduced glutathione/oxidized glutathione) and gluthathione peroxidase are essential to 
prevent toxicity caused by an acute increase in ROS production inside the mitochondrial 
matrix [116]. Therefore, it was hypothesized that GSSG/GSH ratio could be an acute 
modulator of ABCB10 activity and thus of its antioxidant function. In other words, 
conditions of high GSSG/GSH in the matrix, associated with increased oxidative stress, 
would activate ABCB10 to perform its function. Thus, the effect of glutathione (reduced 
or oxidized) on photolabeling of ABCB10 with 8-azido-ATP [γ] biotin was studied. In 
the presence of increasing concentrations of either GSH or GSSG, the biotin signals were 
decreased (Figure 6.2.2.A. & B.). As the biotin group is labeled in the γ-phosphate of the 
8-azido-ATP molecule, the decreased ABCB10 biotin signals could be explained by 
either increased ATP hydrolysis activity or decreased ATP binding. To specifically 
examine the ATP binding ability, [α-32P] 8-azido-ATP was utilized for photolabeling.  
The advantage of the radioactive labeling of the α-phosphate is that it is not released 
during ATP hydrolysis. Therefore, changes in the levels of radioactive signals in 
ABCB10 could only be explained by the changes in 8-azido-ATP binding. Consistent 
with the hypothesis, the result shows that the increasing concentrations of oxidized 
glutathione (GSSG) did not change the radioactive intensities in ABCB while the reduced 
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glutathione (GSH) decreased the radioactive intensities in ABCB10 (Figure 6.2.2.C.). 
Therefore it can be concluded that GSSG triggered 8-azido-ATP hydrolysis by ABCB10, 
while GSH reduced 8-azido-ATP binding to ABCB10. 
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Figure 6.2.2. Effects of GSH and GSSG on photolabeling by 8-azido-ATP. A) and B) 
Increasing concentrations of GSH or GSSG decreased the biotin signal during the 
photolabeling of ABCB10 with 8-azido-ATP [γ] biotin. Representative Western blot 
analyses are shown. The bar graphs show the ExtrAvidin signal intensities normalized 
with that with no GSH or GSSG treatment. Three independent experiments were 
performed and data are shown as mean + SEM. *p<0.05 vs. the signal in 0mM GSH or 
GSSG treatment (t-test). C) A representative autoradiography image and the bar graph 
show that increased concentrations of GSH decreased the radioactive intensities during 
the photolabeling of ABCB10 with [α-32P] 8-azido-ATP, whereas GSSG did not. Two 
independent experiments were conducted and data are shown as mean + SD of the 2 
experiments. 
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CHAPTER SEVEN 
GLUTATHIONYLATION OF ABCB10 
 
7.1. Background 
Glutathione can modulate protein activity through gluthationylation of certain residues. 
For example, there is a report showing that glutathionylation of Cys-1344 of CFTR 
inhibits its channel activity [117]. Therefore, determining cysteine residues localization 
and orientation in ABCB10 structure could be helpful to understand whether ABCB10 
cysteine gluthationylation is a feasible mechanism by which glutathione regulates 
ABCB10 ATP binding and hydrolysis activity.  
Mouse ABCB10 has one cysteine in the mitochondrial targeting sequence, Cys79 and 
five in the mature protein sequence (Cys180, Cys185, Cys189, Cys547 and Cys675). So 
far the crystal structure of human ABCB10 is solved [67]. Four of these cysteines are 
conserved from mouse to human: Cys102 in the mitochondrial targeting sequence of 
human ABCB10 aligns with Cys79 in the mouse sequence; Cys215 (human) aligns with 
Cys180 (mouse); Cys224 (human) aligns with Cys189 (mouse); and Cys582 (human) 
aligns with Cys547 (mouse). The human sequence has three additional cysteines in the 
mitochondrial targetting sequence. The mouse sequence has two additional cysteines in 
the folded protein, Cys185 and Cys675, which align with Ala220 and Thr710. Here the 
available human ABCB10 crystal structure (Figure 7.1.) is used to show the positions of 
the cysteine residues in the mouse ABCB10 structure. The cysteine residues that are 
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conserved from mouse to human are shown in red and the residues that are cysteines in 
the mouse sequence, but are changed in the human sequence are shown in orange.  
 
 
 
Figure 7.1. Mouse cysteine residues within human ABCB10 structure. The structure 
of the human ABCB10 (pdb:4ayx): The trans-membrane domains (TMDs) of the two 
chains are shown in green and cyan and the nucleotide binding domains (NBDs) are 
shown in dark green and dark blue. The three conserved cysteines, Cys215/Cys180 
(human/mouse numbering), Cys224/Cys189 and Cys582/Cys547 are shown in red. The 
residues of the human sequence that are cysteines in the mouse sequence (Ala220/Cys180 
and Thr710/Cys675) are shown in orange. The residue numbering on the figure is for the 
mouse sequence. The approximate extent of the mitochondrial inner membrane is shown 
with two black lines. 
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7.2. Results 
In order for the mitochondrial matrix glutathione levels to affect ABCB10 function, it 
would be necessary for the glutathionylated cysteine residues to be localized in the 
mitochondrial matrix. For the mouse ABCB10, Cys180, Cys185 and Cys189 are all at the 
apex of the protein. Cys185 and Cys189 face into the membrane space, not into the 
protein. Cys180 faces into the transmembrane helix bundle space. None of these residues 
would be exposed to the mitochondrial matrix. The only two residues that are inside the 
matrix are Cys547 and Cys675. Therefore these two cysteines were examined for 
glutathionylation.   
The biotin-labeled glutathione (GSH-biotin) was used to detect glutathionylation of 
ABCB10. The specificity of this glutathionylation is confirmed by two different results. 
First, the extent of ABCB10 glutathionylation was high when the treatment of SMPs with 
GSH-biotin was performed at lower pH values since the di-sulfide bond formation occurs 
more easily at the acidic environment (Figure 7.2.A.). Secondly, this glutathionylation of 
ABCB10 disappeared in the presence of the reductant agent DTT, which prevents the di-
sulfide bond formation (Figure 7.2.B.). Further a decreased glutathionylation signal was 
found in the C547A mutant and this decreased signal did not occur in the C675A mutant 
(Figure 7.2.C.). Therefore it could be concluded that the cysteine residue at the position 
547 is the site for glutathionylation. 
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Figure 7.2. The glutathionylation of ABCB10. A) Glutathionylation of ABCB10 was 
detected with ExtrAvdin-HRP by Western blot. Glutathionylation could be detected in 
pH values around physiological range. At pH 5.5, the acidic environment made protein 
precipitate, which impeded detection of ABCB10 protein. B) The reductant agent DTT at 
10mM prevented glutathionylation of ABCB10 in SMPs (the detection was performed as 
in A, with ExtrAvidin-HRP after ABCB10 immunoprecipitation). C) The mutation of 
cysteine at the position 547 (C547A) decreased the ExtrAvidin-HRP signal intensity, 
indicating a decreased glutathionylation. The mutation C675A did not decrease the signal 
intensity. 
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CHAPTER EIGHT 
DISCUSSION 
 
This dissertation describes the use of the 8-azido-ATP photolabeling system to define the 
ATP binding and hydrolysis properties of ABCB10. This is the first time that the 
biochemistry of ABCB10 was studied independently of cells. During the experiment the 
physiological function of ABCB10 was basically maintained because the research was 
conducted on the re-organized mitochondrial inner membrane or SMPs where ABCB10 
was localized. By labeling the γ-phosphate with biotin and detecting it after Western blot, 
one can figure out changes in ATP binding and hydrolysis after specific treatment. The 
decreased biotin detection could indicate decreased 8-azido-ATP binding or increased 8-
azido-ATP hydrolysis. Also the α-phosphate could be labeled by containing a radioactive 
32
P. However the decreased detection of radioactivity could always be explained by 
decreased 8-azido-ATP binding and is not related to the increased 8-azido-ATP 
hydrolysis since the α-phosphate is not released during hydrolysis.  
In some ABC transporters, the ATP binding was found to be stabilized by hydrogen bond 
interactions of the oxygen atoms from the β- and γ-phosphates of ATP with the conserved 
third glycine and lysine residues in the Walker A motif [32]. Consistent with this, in 
ABCB10, the mutation of the conserved residues in the Walker A motif, either G497A or 
K498R, decreased 8-azido-ATP binding. This result is also consistent with the recent 
analysis of the ABCB10 structure, showing that oxygen atoms from the β-phosphate 
might form hydrogen bonds with the Walker A glycine and lysine residues [67]. A 
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similar result was obtained when characterizing MDR1/ABCB1, another ABC transporter 
protein that belongs to sub-family B. This study shows that the mutation of lysine in the 
Walker A motif in both MDR1 NBD monomers rather than in one monomer decreased 
ATP binding affinity [39]. Another report claims that the ATP binding was not affected 
when one or both MDR1 NBD monomers had the conserved glycine and/or lysine 
mutated while the transport activity was still impaired. However, by looking carefully at 
the figures in that report, it could be found that the 8-azido-ATP photolabeling was 
actually decreased in all the five mutants, which are mutations of glycine in either of the 
two monomers, mutations of lysine in either of the two monomers, and mutations of 
lysine in both monomers. The authors claimed that the lower 8-azido-ATP photolabeling 
intensities were correlated with the lower amount of proteins produced in mutants, and 
therefore concluded that there was no decreased ATP binding in those mutants. 
Nevertheless they did not normalize the 8-azido-ATP photolabeling intensities with the 
MDR1 protein blot intensities. Also they only showed one experiment and did not 
perform statistical analysis. On the other hand, this study found that there was a drug 
survival and drug accumulation in the cells expressing those mutated MDR1, which 
means that the drug resistance function was damaged in the mutated MDR1 [40]. If their 
conclusion that the 8-azido-ATP binding is not affected is correct, then the observed 
decreased drug resistance function must me due to the decreased ATP hydrolysis. In this 
conclusion, these conserved glycine and lysine residues in the Walker A motif are also 
involved in ATP hydrolysis. In the experiment of ABCB10, the photolabeling with 8-
azido-ATP detected by the biotin signal was decreased either in the third glycine-mutated 
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Walker A motif or in the lysine-mutated Walker A motif. This decrease could not be as a 
result of increased release of the biotin-labeled γ-phosphate due to an increased 8-azido-
ATP hydrolysis because those residues are so conserved that the replacement of them 
with other amino acids should not enhance NBDs’ ability to utilize ATP. Therefore only 
the decreased 8-azido-ATP binding by the mutants could be an explanation for that result. 
The mutation of the second glycine residue (G551D) in the C-loop motif has been 
identified in the CFTR gene of cystic fibrosis patients, showing that it is functionally 
important. Most patients with this mutation suffered from moderate to severe pulmonary 
disease as well as exocrine pancreatic insufficiency [101]. A study of the TAP protein 
found that mutation of glycine in the C-loop motif impaired peptide transport due to the 
decreased ATP hydrolysis, while the ATP binding capacity was not affected [43]. In the 
Walker B motif, the conserved glutamate residue in the end of the motif is an important 
catalytic residue for ATP hydrolysis, but it is unlikely to be a residue that could 
determine ATP binding [37]. In ABCB10, a decreased ATP hydrolysis activity was found 
either in the mutation of the second glycine in the C-loop motif (G602V or G602D) or in 
the mutation of the glutamate residue in the end of the Walker B motif (E624Q) by 
observing an increase in the γ-phosphate-tagged biotin signal in those mutations. This 
signal increase was caused by the decreased γ-phosphate release. The results show that 
the role of these residues in ABCB10 is equivalent to those in other ABC transporters, 
which means that the C-loop and the glutamate in the end of the Walker B motif are 
essential for the ATP hydrolysis activity in ABCB10.  
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As ABCB10 is an ABC transporter, it is expected that if a molecular entity increases ATP 
hydrolysis by ABCB10, it could be a potential substrate transported by ABCB10 and/or a 
potential modulator of its transport function. This means that the 8-azido-ATP 
photolabeling approach can be used to examine if a molecular entity is a potential 
substrate of ABCB10. This is relevant, as no substrates for ABCB10 have been 
determined so far. ABCB10 was shown to be required for proper hemoglobin synthesis 
[15]. Given that ABCB10 is a transporter with its NBDs facing the matrix, it was 
hypothesized that ABCB10 could be the unidentified dALA (heme precursor) exporter. 
The 8-azido-ATP photolabeling system shows that a high concentration of dALA (5 mM) 
decreased the 8-azido-ATP [γ] biotin photolabeling in ABCB10. Since dALA is formed 
by the condensation of glycine and succinyl-CoA, catalyzed by ALAS which has Km 
values of 1.9 mM for glycine and 17 μM for succinyl-CoA [118], and the concentration 
of synthesized dALA is at micromolar range even the concentrations of both precursors 
glycine and succinyl-CoA are close to 10 mM [119], it can be inferred that the 
physiological range of dALA concentration is at micromolar level. While according to 
the 8-azido-ATP photolabeling result, this concentration is not high enough to cause a 
decrease in photolabeling. Therefore the observed decrease in photolabeling at the high 
dALA concentration does not result in a conclusion that dALA is an exported substrate of 
ABCB10. This is further supported by the observation of PPIX accumulation in the 
ABCB10 KO erythroid cells, which means dALA export was not impaired in the 
ABCB10 KO cells [73]. Although a report showed that dALA rescues some defects 
caused by ABCB10 down-regulated cardiac cell lines, this rescue did not exist in primary 
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erythroid progenitors with complete abrogation of ABCB10 expression [115]. This 
suggests that the rescue effect of dALA may result from some other mechanisms rather 
than directly involvement of the dALA-promoted heme biosynthesis pathway. 
The mitochondrial electron transport chain is a major site of superoxide generation. This 
superoxide can be dismutated to H2O2 by superoxide dismutase 2, located in the 
mitochondrial matrix. H2O2 is then detoxified via mitochondrial glutathione peroxidases 
by turning GSH into GSSG and thus avoiding H2O2 diffusion to other cellular 
compartments. GSSG can be reduced back to GSH via the mitochondrial glutathione 
reductase (using NADPH) or could potentially be transported out of mitochondria 
(although the latter is controversial) [82]. If this export of GSSG exists, the GSH-
determined reduced mitochondrial environment could be maintained independently of 
glutathione reductase activity or the NADPH/NADP
+
 redox pair. It is important to note 
that the GSH amount in mitochondria is around 10mM, and the ratio of GSH:GSSG is 
20:1 to 40:1 [79, 120]. For this reason the effect of GSH or GSSG on the 8-azido-ATP 
binding or hydrolysis is examined in the 8-azido-ATP photolabeling system. And it was 
observed that increased concentrations of GSSG decreased the biotin signals when using 
8-azido-ATP [γ] biotin while there was no obvious decrease in the radioactive intensities 
when using [α-32P] 8-azido-ATP. These results suggest that GSSG actually triggered 8-
azido-ATP hydrolysis. According to the fact that an ABCB10 substrate could trigger 
ATP hydrolysis, it is therefore possible that GSSG could be one of the potential 
substrates of ABCB10 and that the transport of GSSG out of mitochondria could 
maintain the reduced (high GSH) environment inside mitochondria. This could explain 
 
 
 
 
85 
the anti-oxidant role of ABCB10. The advantage of transport of GSSG from the 
mitochondria into the cytosol is that a large portion of GSSG can be reduced into GSH in 
the cytosol rather than inside mitochondria. Therefore, the reducing equivalent NADPH 
inside mitochondria can be saved for other mitochondrial functions such as tricyclic acid 
cycling. And the GSH converted from GSSG in the cytosol can go back into the 
mitochondria for maintenance of reducing environment.  
On the other hand, it was observed that increased concentrations of GSH decreased both 
biotin signals and radioactive intensity when using 8-azido-ATP [γ] biotin and [α-32P] 8-
azido-ATP, respectively, which suggests that GSH decreased 8-azido-ATP binding. The 
presence of more GSH inside mitochondria indicates that the reduced environment is well 
preserved and therefore ABCB10, as a protector against ROS damage inside 
mitochondria, needs to work less to transport ROS-associated materials such as GSSG or 
GS-X (glutathione-conjugated substrate X) out of mitochondria [57, 84, 85]. Therefore 
less energy needs to be produced via ATP hydrolysis by ABCB10. That could explain 
why the ATP binding by ABCB10 is decreased in the GSH-abundant environment. Then 
it was hypothesized that GSH regulates ATP binding via glutathionylation of the cysteine 
residues in NBDs. Indeed the crystal structure study of Atm1, a yeast mitochondrial ABC 
transporter and also an ortholog of human ABCB7, has shown a glutathione binding site. 
And this site includes an amino acid residue whose mutation is related to the sideroblastic 
anemia XLSA/A [121]. 
For ATP hydrolysis, the two NBDs would have to come together to form a close packed 
open outwards arrangement, as seen in the MsbA and Sav1866 structures [122, 123]. 
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Residues involved in large changes in ATPase activity would be expected to lie at the 
interface between NBDs or the TMDs, or in a region that is important for activity or 
changes in conformation. None of the cysteine residues of ABCB10 lie in this region. 
Three out of the 5 cysteines are exposed to the inner membrane but closer to the inter-
membrane space, and are relatively far from NBD. The modification of these 3 cysteines 
would likely require an interaction with a membrane protein (integral and/or attached). 
The fourth cysteine (Cys547) is inside the mitochondrial matrix and lies near the 
interface between NBD in one monomer and the coupling helix from the other monomer. 
Its modification could potentially interfere with the interactions between NBD and the 
coupling helices. Therefore, this is a hypothetically plausible mechanism by which 
glutathionylation could alter ATPase activity. The fifth cysteine, Cys675, is located in 
NBD in a region outside NBD dimer interface. Therefore, a modification in this cysteine 
could potentially affect ATPase by an indirect mechanism that would not directly 
interfere with NBD coming together, a step required for ATP hydrolysis. 
In this regard, two cysteines (C547 and C675) inside mitochondrial matrix were 
examined for glutathionylation and it was found that Cys547 was the site of 
glutathionylation. This cysteine is located between the Walker A and the C-loop motifs. 
A previous report shows that the glutathionylation regulation also exists in 
CFTR/ABCC7, another ABC transporter. When CFTR channels are glutathionylated, 
they exhibit very low open rate even in the presence of normal concentration of ATP, 
indicating that the channels are regulated by ROS inside cells. The glutathionylated 
cysteine in CFTR is C1344, also between the Walker A motif (GRTGSGKST in CFTR) 
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and the C-loop motif (LSHGH in CFTR). And that glutathionylation disrupts ATP 
binding or the link between ATP binding and the CFTR channel opening [117], which is 
similar to what was found in ABCB10. In summary, the GSSG-triggered ATP hydrolysis 
and the GSH-regulated ATP binding could represent the molecular mechanism by which 
the ratio of GSH/GSSG modulates the ATP hydrolysis activity of ABCB10, in response 
to the redox state changes inside mitochondria. 
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APPENDIX 
MITOCHONDRIAL REDOX STATES IN THE WT AND ABCB10 KNOCKOUT 
ENDOTHELIAL CELLS 
 
8.1. Background 
Since ABCB10 plays a role in protection against ROS damage inside mitochondria and 
the decreased protection effect is responsible for the reduced heart recovery after 
ischemia-reperfusion damage in the ABCB10 +/- mice [78], it is interesting to study the 
redox states in the mitochondria of WT or ABCB10 knockout heart endothelial cells. 
roGFP2, or reduction-oxidation sensitive green fluorescent protein 2, is used for the in 
vivo observation of redox states inside mitochondria. It is an analog of GFP and has two 
cysteines introduced at the amino acid positions 147 and 204 within the β barrel of the 
GFP molecule. In the oxidized state the two cysteines form a disulfide, while in the 
reduced state they exist as a dithiol. These two states of thiols determine the fluorescent 
excitation behavior of roGFP2. The fluorescent emission of roGFP2 is measured at the 
wavelength 510nm and there are two emission intensity peaks which are acquired if 
roGFP2 is excited at the wavelengths around 400nm and 490nm. The oxidized state 
increases the 400nm-excited emission peak while decreases the 490nm-excited emission 
peak. (Figure 8.1.1.). These properties make roGFP2 a probe to detect redox states in cell. 
In reality, roGFP2 is genetically fused with glutaredoxin-1 (Grx1) to measure the redox 
potential of the glutathione redox couple, or is fused with H2O2-sensitive thiol peroxidase 
to measure the relative differences in H2O2 concentrations (Figure 8.1.2.) [124].  Further, 
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in order to make in vivo measurement of the redox states inside mitochondria, roGFP2-
Grx1 or roGFP2-Orp1 is fused with a mitochondrial targeting sequence so that the probe 
can be localized inside mitochondria.  
 
 
 
 
 
Figure 8.1.1. Fluorescent intensity peaks of roGFP2 at 510nm emission wavelength 
(Morgan B, Sobotta MC, Dick TP, 2011). Oxidized state (blue line) leads to high 
emission peak at 405nm excitation wavelength and low emission peak at 488nm 
excitation wavelength. Reduced state (red line) leads to low emission peak at 405nm 
excitation wavelength and high emission peak at 488nm excitation wavelength.  
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Figure 8.1.2. Conformational changes of roGFP2 in the oxidized state (Morgan B, 
Sobotta MC, Dick TP, 2011).  A) In the presence of GSSG, Grx1 is S-glutathionylated 
to form GS-Grx1. One of the cysteine residues in roGFP2 attacks GS-Grx1, leading to the 
transmission of S-glutathionylation to roGFP2, followed by the formation of a disulfide 
bond within the roGFP2 molecule. This process is reversible. B) In the presence of H2O2, 
a sulfenic acid group is formed in Orp1, followed by the formation of a disulfide bond 
which is later transmitted to roGFP2. This process is irreversible. 
 
8.2. Methods 
8.2.1. Isolation of mouse heart endothelial cells 
Mice were euthanized using CO2 chamber and sprayed with 70% ethanol. Hearts were 
removed as sterilely as possible, cut in half transverse and rinsed in cold HBSS buffer 
supplemented with 100x antibiotic/antimycotic. Then hearts were transferred into C-
Tubes containing 4.7ml HBSS with 300µl collagenase II and 10µl DNAseI, followed by 
whirring in machine (Gentle MACS dissociator) using the program m_heart_01. Hearts 
were incubated in 37°C for 30min and were turned up and down for several times every 5 
minutes. Hearts were then whirred in machine again using the program m_heart_02. 
Centrifugation was performed to collect samples at C-Tube bottom. Samples were 
resuspended and went through 70µm cell strainer into 50ml tube, washed with 5ml 
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HBSS, centrifuged at 500g for 7min, resuspended in 10ml MACS running buffer 
supplemented with 10x RBC lysis solution, incubated for 2min at room temperature, 
washed once and finally resuspended in 80µl MACS running buffer. 1µl of anti-mouse 
CD31 antibody were added into the suspension followed by incubation on ice for 15min. 
Samples were washed once and resuspended again with 80µl MACS running buffer. 20µl 
of anti-rat IgG microbeads were added into the suspension followed by incubation on ice 
for 15min. Samples were washed once and resuspended with 500µl MACS running 
buffer. Heart endothelial cells were then isolated after letting samples running through 
the MACS cell separator. Cells were resuspended in EBM-2 endothelial cell growth 
media supplemented with 10% FBS, 100x  antibiotic/antimycotic and 0.005% endothelial 
mitogen, plated in gelatin-coated dishes, and cultured at 37°C in 5% CO2 without any 
moving of the dishes for at least one week to allow cells to propagate.  
8.2.2. Infection of mouse heart endothelial cells with Ad-Cre-dsRed, Ad-mito-
roGFP2-Orp1 and/or Ad-mito-roGFP2-Grx1 adenoviruses 
When isolated heart endothelial cells have been propagated, they were cultured in 
gelatin-coated confocal dishes. Cells at a confluence of 70% were infected with 
adenoviruses Ad-Cre-dsRed (100MOI) together with or without Ad-mito-roGFP-Grx1 
(1MOI) or Ad-mito-roGFP-Orp1 (1MOI). Cells infected with Ad-Cre-dsRed expressed 
Cre recombinase that could specifically knock out ABCB10 gene in the endothelial cells 
isolated from ABCB10-LoxP mice. After 48h, the Ad-Cre-dsRed infection efficiency was 
determined by observation of red fluorescence under fluorescent microscopy. And the 
Ad-mito-roGFP-Grx1 or Ad-mito-roGFP-Orp1 infection efficiency was determined by 
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observation of green fluorescent mitochondria under fluorescent microscopy (Figure 
8.2.2.). The ABCB10 knockout in endothelial cells was confirmed by real time PCR.  
 
 
 
Figure 8.2.2. Mouse endothelial cells expressing Cre-dsRed and roGFP2-Grx1. 
Mouse endothelial cells were co-infected with Ad-Cre-dsRed and Ad-mito-roGFP2-
Grx1. Infection with Ad-Cre-dsRed was confirmed by observing red fluorescence inside 
cells (595nm excitation wavelength and 615nm emission wavelength). Infection with Ad-
mito-roGFP2-Grx1 was confirmed by observing green fluorescent mitochondria (488nm 
excitation wavelength and 510nm emission wavelength). Olympus DSU spinning disk 
confocal microscope was used for fluorescence observation (40x magnification). 
 
8.2.3. Confirmation of ABCB10 knockout by real time PCR 
Total RNA from Ad-Cre-dsRed-infected WT or ABCB10-LoxP endothelial cells was 
isolated using the Qiagen RNesay mini kit. mRNA was reverse-transcribed into cDNA 
using the high capacity RNA-to-cDNA kit with the reaction condition as 37°C 60min and 
95°C 5min. For real time PCR, 10ng cDNA was used for each reaction. GAPDH gene 
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was used as endogenous control. Relative mRNA expression was calculated using the 
comparative CT method (∆∆CT method). The ABCB10 mRNA level in Ad-Cre-dsRed-
infected ABCB10-LoxP cells was only 10% of that in the WT Ad-Cre-dsRed-infected 
cells, indicating that ACB10 knockout was successful. 
 
Table 8.2.3. Relative ABCB10 mRNA levels in Ad-Cre-dsRed-infected WT and 
ABCB10-LoxP endothelial cells 
Sample ABCB10 
Average CT 
GAPDH 
Average CT 
∆CT 
(ABCB10 CT - 
GAPDH CT) 
∆∆CT 
(∆CT WT- 
∆CT KO) 
 
Relative 
mRNA level 
(2
-∆∆CT
) 
 
WT 24.41±0.20 22.41±0.01 2.00±0.14 0.00±0.14 1 
(0.91-1.10) 
KO 26.41±0.12 21.16±0.29 5.25±0.18 3.25±0.18 0.11 
(0.09-0.12) 
 
 
8.2.4. Measurement of mitochondrial redox states in WT and ABCB10-knockout 
endothelial cells 
Diamide is a thiol oxidant that oxidizes GSH to GSSG. Redox states inside mitochondria 
of mouse heart endothelial cells before and after diamide treatment were measured by the 
probe mito-roGFP2-Grx1. In detail, endothelial cells from WT and ABCB10-LoxP mice 
were co-infected with Ad-Cre-dsRed (100MOI) and Ad-mito-roGFP2-Grx1 (1MOI). 48h 
after infection, the mitochondrial fluorescent intensities were measured at 488nm and 
390nm excitation wavelengths together with an emission window around 510nm, using 
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Olympus DSU spinning disk confocal microscope. Then 500µM diamide was added into 
the media and the mitochondrial fluorescent intensities were measured again 10min later.  
The probe mito-roGFP2-Orp1 was also used for measurement. Shortly, infected cells 
before and after 10min 200µM tert-butyl hydroperoxide treatment were imaged at 488nm 
and 405nm excitation wavelengths together with an emission window around 510nm, 
using Zeiss LSM 710-Live Duo scan confocal microscope. 
8.2.5. Analysis of mitochondrial redox states 
Images were analyzed using the software Metamorph to acquire the integrated 
mitochondrial fluorescent intensity in each cell. More specifically, after opening an 
image file in Metamorph, an intensity threshold was applied to acquire the clearest 
mitochondrial structure. The threshold for one individual cell before and after drug 
treatment was kept the same for the same excitation wavelength. Images then underwent 
morphology filter by selecting circle filter shape and 2 pixels. After that, the whole 
cellular area was circumscribed for region measurement and acquirement of integrated 
intensity value.  
A redox state in one cell could be calculated as integrated intensity at 390nm divided by 
integrated intensity at 488nm (spinning disk confocal microscope), or integrated intensity 
at 405nm divided by integrated intensity at 488nm (Zeiss confocal microscope). A 
change in redox state in one cell could be calculated as redox state after drug treatment 
divided by redox state at basal condition. Changes in redox states were compared 
between WT and ABCB10-knockout endothelial cells. The higher value of change 
indicated higher oxidized state after drug treatment. 
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8.3. Results 
8.3.1. Changes in redox states in WT and ABCB10-knockout endothelial cells after 
tert-butyl hydroperoxide treatment 
When mito-roGFP2-Orp1 was used as a probe, 15min after 200µM tert-butyl 
hydroperoxide treatment, the fluorescent-intensity-determined change in redox state was 
higher in the mitochondria of ABCB10-knockout endothelial cells than that in the 
mitochondria of WT cells, suggesting that the mitochondrial environment inside 
ABCB10-knockout cells were in more oxidized after tert-butyl hydroperoxide treatment. 
This result is consistent with the previous conclusion that ABCB10 plays a role in 
protection against ROS inside mitochondria (Figure 8.3.1.).  
8.3.2. Changes in redox states in WT and ABCB10-knockout endothelial cells after 
diamide treatment 
Further, when mito-roGFP2-Grx1 was used as a probe, 10min after 500µM diamide 
treatment, the mitochondrial environment inside ABCB10-knockout endothelial cells was 
more oxidized than that inside WT cells, suggesting that ABCB10 helps maintain higher 
GSH/GSSG ratio inside mitochondria, which is consistent with the above result (Figure 
8.3.2.).  
 
 
 
 
 
96 
 
A 
 
 
 
B 
 
 
 
 
97 
Figure 8.3.1. Changes in redox states after tert-butyl hydroperoxide treatment. A) 
Relative redox state change was calculated as I405 / I488 after 10min tert-butyl 
hydroperoxide treatment divided by I405 / I488 at basal condition. I405 represents 
integrated fluorescent intensity at 405nm excitation wavelength. I488 represents 
integrated fluorescent intensity at 488nm excitation wavelength. After 200µM tert-butyl 
hydroperoxide treatment, the mitochondrial environment inside the ABCB10 KO mouse 
heart endothelial cells were more oxidized (represented by bigger change in redox state) 
than that inside the WT mouse heart endothelial cells. 10 cells were measured in each 
group. Data are shown as mean + SD, *p<0.05 (t test). B) Typical images in the first and 
second rows show observed fluorescence excited by 488nm (reduced state) and 405nm 
(oxidized state) wavelengths respectively before or after 200µM tert-butyl hydroperoxide 
treatment. The images in the bottom row show that cells were well infected with Ad-Cre-
dsRed, whose fluorescence was observed via 595nm excitation and 615nm emission 
wavelengths. Images were taken by using LSM 710-Live Duo scan 2-photon confocal 
microscope imaging system (20x magnification). 
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Figure 8.3.2. Changes in redox states after diamide treatment. A) Relative redox state 
change was calculated as I390 / I488 after 10min diamide treatment divided by I390 / 
I488 at basal condition. I390 represents integrated fluorescent intensity at 390nm 
excitation wavelength. I488 represents integrated fluorescent intensity at 488nm 
excitation wavelength. After 500µM diamide treatment, the mitochondrial environment 
inside the ABCB10 KO mouse heart endothelial cells were more oxidized (represented 
by bigger change in redox state) than that inside the WT mouse heart endothelial cells. 7 
cells were measured in each group. Data are shown as mean + SD, *p<0.05 (t test). B) 
Typical images in the first and second rows show observed fluorescence excited by 
488nm (reduced state) and 390nm (oxidized state) wavelengths respectively before or 
after 500µM diamide treatment. The images in the bottom row show that cells were well 
infected with Ad-Cre-dsRed, whose fluorescence were observed via 595nm excitation 
and 615nm emission wavelengths. Images were taken by using DSU spinning disk 
confocal microscope (20x magnification). 
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